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ABSTRACT 
The delivery of therapeutic molecules to the central nervous system (CNS) is hindered by 
poor delivery across the blood-brain barrier (BBB). Various therapeutic approaches have been 
developed but current delivery methods are inefficient, damage the BBB, and often lead to 
immune response. Therefore, successful treatment of CNS disorders requires the discovery of 
effective and safer drugs that are able to get across this biological barrier. Cell-penetrating 
peptides (CPPs) may present an opportunity to develop a drug delivery system that enables 
cargo trafficking through the cellular membrane and is capable of carrying different active 
macromolecules into the brain. Previous studies reported peptide derived from type 2 capsid 
protein from the Dengue Virus (DEN2C) can be employed as a CPP for brain delivery, more 
specifically the sequence corresponding to the third a-helix (PepH3). PepH3 specifically 
interacts with anionic membranes, characteristic of brain endothelial cells (BECs). In addition, 
preliminary results show that the translocation mechanism is receptor-independent, possibly 
adsorptive-mediated transcytosis. The main purpose of this thesis was to elucidate the 
translocation mechanism of PepH3 through BECs. To accomplish this goal, PepH3 was 
conjugated to green fluorescent protein (GFP) through recombinant protein technologies. Next, 
GFP-H3 interaction with BECs was evaluated, with a percentage of translocation of 21.63% ± 
4.81 and uptake of 0.18% ± 0.10. Furthermore, inhibitory conditions and cellular staining were 
applied to BECs to understand cellular trafficking of GFP-H3. It was found that the cellular 
uptake of GFP-H3 is energy-dependent, evidenced by a decrease in translocation (4.63% ± 0.79) 
when cells are incubated at 4°C. In addition, of GFP-H3 translocation through BECs is inhibited 
by dynasore, MbCD and EIPA, confirming that an endocytic process is involved. Together the 
results reveal that PepH3 might function as shuttle for brain drug delivery, by interacting with 
anionic BECs, followed by internalization via caveolae-dependent endocytosis. By escaping 
lysosomes, the peptide is exocytosed into the brain side. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: cell-penetrating peptides; blood-brain barrier; drug delivery systems; 
translocation mechanisms; endocytosis; dengue virus capsid protein. 
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RESUMO 
Devido à existência da barreira hemato-encefálica (BHE), a entrega de moléculas 
terapêuticas no sistema nervoso central (SNC) constitui um dos grandes desafios da actualidade. 
Ao longo dos anos, têm sido desenvolvidas novas terapias de combate às doenças do SNC. No 
entanto, estas são pouco eficientes, danificam a integridade da BHE ou activam respostas 
imunológicas. O sucesso no tratamento destas doenças requer a descoberta de fármacos, 
eficazes e seguros, capazes de atravessar esta barreira biológica. Para tal, péptidos capazes de a 
translocar são a base para desenvolver um sistema de entrega de fármacos que permita o 
transporte de moléculas através da BHE e consequentemente para o cérebro. Estudos efectuados 
com a proteína tipo 2 da cápside do vírus da Dengue, especificamente a sequência 
correspondente à terceira hélice (PepH3) demonstraram que esta pode servir de modelo para 
potenciais péptidos translocadores. O PepH3 interage especificamente com membranas 
aniónicas, características das células endoteliais cerebrais (CECs). Além disso, resultados 
preliminares demonstraram que o mecanismo de translocação é independente de receptor. O 
principal objectivo desta tese foi elucidar o mecanismo pelo qual o PepH3 atravessa as CECs. 
Para tal, o PepH3 foi conjugado com a GFP através de técnicas de biologia molecular. De 
seguida, foi avaliada a interacção da GFP-H3 com as CECs, tendo-se obtido uma percentagem 
de translocação de 21.63% ± 4.81 e 0.18% ± 0.10 de absorção. De modo a compreender a rota 
celular da GFP-H3, foram efectuados estudos quer com inibidores quer através da marcação dos 
compartimentos celulares tendo-se verificado que a translocação da GFP-H3 é dependente de 
energia pois, há um decréscimo da percentagem de translocação (4.63% ± 0.79) quando as 
células são incubadas a 4ºC. Além disso, verificou-se também que dyansore, MbCD e EIPA, 
funcionam como inibidores, confirmando que a endocitose está envolvida na sua internalização. 
Os resultados obtidos neste trabalho, revelam que o PepH3 pode funcionar como transportador 
de fármacos através da BHE através da interacção com CECs seguido da internalização através 
de endocitose dependente de caveolae.  
  
 
 
 
 
 
 
 
 
 
 
Palavras-chave: péptidos com capacidade de translocação; barreira hemato-encefálica; 
sistemas de libertação controlada; mecanismos de translocação; endocitose; proteína da cápside 
do vírus da dengue. 
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I.  INTRODUCTION 
One the biggest challenges in biomedical sciences is the discovery of therapeutic agents that 
act only where needed. Many human diseases, including neurodegenerative disorders such as 
multiple sclerosis, Huntington’s, Parkinson’s and Alzheimer diseases, are presently incurable. 
The last one is considered the sixth leading cause of all deaths and the fifth leading cause of 
death in people over 65 years.1–3 During the past decades, many new therapeutic approaches 
have been developed but the current methods, either invasive surgical procedures or some 
pharmacological methods such as chemical drugs, are associated with low transfer efficiency, 
damages in brain membrane integrity and often led to immune response.2,4–6 Therefore, the 
biggest challenge in the treatment of central nervous system (CNS) diseases, is to discover new 
drugs that are safe and effective.7 
 
I.1. Challenges in drug delivery: The Blood-brain Barrier  
The main limiting factor to a successfully treat brain diseases is associated to the lack of 
effective delivery of drugs across the blood-brain barrier (BBB).4,8,9 The BBB is the most 
important, selective and dynamic barrier that protects the brain against foreign organisms and 
unwanted substances, preventing 100% of large molecules and approximately 98% of small 
molecules, from accessing the brain.10–12 
The BBB is mainly constituted by specialized endothelial cells that form the walls of the 
capillaries and represents by far the largest interface for blood-brain exchange. Followed by 
basal lamina, a matrix composed of several extracellular proteins that regulates the integrity of 
BBB; astrocytes end-feet that, cover more than 99% of the basal capillary membrane, keeping 
the BBB stability; and pericytes that regulate the BBB development and permeability (Figure 
I.1).13,14  
The endothelial cells are unique, their plasma membrane divides into the apical and 
basolateral membrane, the first which faces the blood and the last the brain tissue. These cells 
are tightly connected by means of adherent junctions (AJ), which help stabilize the cell-cell 
interaction on the junctional zone, and tight junctions (TJ) that are composed for transmembrane 
proteins that effectively seal the paracellular pathway.8,13,15 
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Figure I.1 - Schematic representation of the blood-brain barrier (BBB). The BBB is mainly constituted by 
endothelial cells that form the walls of capillaries. These cells are connected by adherent juntions (AJ) and tight 
junctions(TJ) and their integrity is regulated by the  basal lamina, astrocytes cover the basal capillary membrane and 
perycites regulate the development and permeability of the BBB.16 
Although the main function of the BBB is to protect the brain, the brain is not isolated and 
endothelial cells are permeable to many essential water-soluble nutrients and metabolites 
allowing them to be carried to the brain. Thus, several transport routes across the BBB have 
been identified that including two principal systems, an energy-independent direct translocation 
or an energy-dependent endocytosis system.8,13,16 
Nowadays, one of the biggest obstacles in drug delivery, is to find molecules that can 
transport therapeutic drugs across biological membranes like the BBB. Polypeptides and 
oligonucleotides are generally considered to be of limited therapeutic value due to the low 
permeability of the BBB and to their relatively rapid degradation. Nevertheless, over the last 
years, it has been found that some peptides and proteins can penetrate the cell membrane and 
enter the cell working as safe and efficient delivery systems. 
 
I.2. Cell-penetrating peptides: new promising therapeutic molecules 
Cell-penetrating peptides (CPPs) consist of short sequences of amino acids, typically with 5-
30 amino acids, that unlike most peptides are able to cross the cellular membrane and are 
capable of carrying different active macromolecules into cells. CPPs may thus offer new 
opportunities for cellular drug delivery.17–19 
In the late 80s and early 90s, a major revolution in the identification of such transporters was 
recognised. The first CPPs discovered and characterized in 1988 were derived from the Human 
Immunodeficiency Virus (HIV), the Trans-Activator of Transcription (Tat) protein and 
Penetratin (PTT) protein, derived from Antennapedia homeodomain (Antp) a homeobox 
transcription factor of Drosophila melanogaster. Originally, it was discovered that the full-
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length protein translocated the plasma membrane, and subsequently, mapping the domains that 
confer the translocation proprieties to these proteins, allowed the identification of small 
fragments that could efficiently enter the cells. Today, thousands of studies have been 
performed that aimed to characterize and optimize CPPs as cellular delivery agents leading to 
the discovery of many other peptides that represent a promising tool for drug delivery, 
particularly in neurological disorders. They can be associate to other molecules like nucleic 
acids, peptides or proteins as well as drugs and fluorescent or radioactive compounds for 
imaging, and cross the cellular membranes into the cells to deliver the intact cargo.19–24  
 
I.2.1. Classes and Proprieties of Cell-penetrating peptides 
CPPs constitute a very heterogeneous and large group of peptides that is often subdivided 
into three principal classes based on the physicochemical properties of their sequences: cationic, 
hydrophobic and amphipathic.2,23 
The cationic group, containing approximately 83% of sequences, is considered the largest 
class of CPPs. Penetratin and Tat are both cationic peptides and the best-known members of this 
class were derived from it. In additions, cationic peptides group include homo-polymers of 
Arginine and Lysine. Studies based on Arginine homo-polymers (from R3 to R12), have shown 
that this peptide requires a minimal sequence, eight arginine residues (octaarginine, R8), to 
increase the efficiency of cellular uptake. In contrast, the Poly-Lysine besides presenting the 
same positive net charge as arginine, has a reduced cellular uptake, because it lacks the 
guanidine head group. Therefore, charged residues have a crucial role in the cellular uptake of 
cationic CPPs because they develop electrostatic interactions with negatively charges on the 
cellular surface, and thus demonstrate great potential as transmembrane carriers.2,17,23 
Amphipathic CPPs are peptides that present both hydrophilic and hydrophobic parts. These 
peptides can have a highly hydrophilic N-terminus and a mainly hydrophobic C-terminus. 
However, their “amphipathicity” is also dependent of their secondary structure, with all the 
polar residues pointing to one face and the nonpolar residues on the opposite side. Amphipathic 
CPPs group are subdivided in three sub-classes. The first sub-class comprises the chimeric 
peptides such as MPG and Pep-1 that were obtained by covalent attachment of a hydrophobic 
domain to a nuclear localizing signal (NLS) and the peptides derived from natural proteins such 
as pVEC, ARF (1-22) and BPrPr (1-28). The second sub-class is composed of amphipathic a-
helical CPPs like MAP and transportan. These CPPs have hydrophobic and hydrophilic amino 
acids that occupy different faces of the helix. The third sub-class includes b-sheet amphipathic 
CPPs such as VT5, proline-rich amphipathic peptides such as Bac7 and sweet arrow peptide 
(SAP).17,23,25,26 
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The class of hydrophobic CPPs contains peptides from natural amino acids and chemically 
modified peptides. These CPPs have low global net charges because they are mainly composed 
of hydrophobic residues, however, they seem to be able to avoid endosomal degradation 
because they can cross the cell membrane directly. This class is subdivided into peptides based 
on natural amino acids and chemically modified ones, which include stapled peptides, 
prenylated peptides and pepductins.2,17 
DNA-binding and RNA-binding proteins, heparin-binding proteins, homeoproteins, 
antimicrobial peptides, viral proteins and other structures, are several examples of CPPs that can 
be derived from natural proteins or peptides. However, is very important that the CPP are rich in 
basic residues, for example Argines and Lysines, that can interact with negatively charged cell 
surface-bound molecules. 
 
I.3. Peptide PepH3: The peptide derived from Dengue virus 
Typically, the high molecular size and charge of some proteins and other molecules as well 
as their toxicity or vulnerability to enzymatic degradation in the cells, are some of the 
difficulties peptides face to translocate the cellular membrane. So, the viral capsid proteins 
appear to be a great solution to solve these difficulties due to their ability to protect and deliver 
the viral genome into the cells. Nonetheless, employing viral capsids proteins as drug delivery 
systems is limited by their size.27 
Studies reported that the type 2 capsid protein from Dengue Virus (DEN2C) has an interest 
sequence that can be employed as a CPP model. Dengue Viruses are members of the genus 
Flavivirus of enveloped RNA viruses and the capsid C protein is essential to ensure his specific 
encapsidation.28 DEN2C is composed for 100 amino acids an occurs as a homodimer (Figure 
I.2). This protein interacts with both the RNA and the lipid bilayer by two peptides derived from 
two conserved DEN2C protein regions, one is highly cationic (RNA-binding or PepR) and the 
other is hydrophobic (membrane-binding or PepM). Studies with these two proteins have 
demonstrated that the DEN2C protein contains four a-helical regions and an intrinsically 
disordered N-terminal domain. PepM tends to form two highly hydrophobic a-helixes (a2 and 
a3) separated by the Pro-rich segment while PepR forms a single long a-helix (a4), finally, 
studies suggest that the a1 helix may play a role in the initial binding by rearranging the 
structure to further expose the hydrophobic surface (Figure I.2).29–34  
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Figure I.2 - Schematic representation of Dengue Virus. A-Structure of genus Flavivirus virus; B-Amino acid 
sequence of DEN2C protein and it secondary structure (Protein Data Bank); C-Model for DEN2C molecular 
interactions between structural components of genus Flavivirus virus; D-Structure of DEN2C monomer, residues 21-
100; The structures shown are based on PDB file 1R6R and were produced with Chimera v1.10.1. 
Subsequent in vitro studies in BBB model, of these four a-helical domains showed different 
translocation results for each peptide. PepH2 (a2-helix domain) presented a very low BBB 
translocation but a high cellular internalization while PepH4 (a4-helix domain) had moderate 
membrane retention, low cellular internalization but a high BBB translocation. In the case of 
PepH1 (a1-helix domain) and PepH3 (a3-helix domain), these two peptides demonstrated a 
similar high potential to translocate across the BBB. However, in in vivo studies, where these 
two peptides were injected in mice only the PepH3 showed a very efficient brain uptake, a rapid 
excretion in high percentages and the ability to return to blood circulation. In addition, these 
preliminary results also show that the PepH3 translocation mechanism is receptor-independent. 
Possible this peptide uses an adsorptive-mediated transcytosis route, since no peptide was bound 
to cell membrane proteins.35 
Although the discovery of novel efficient CPPs is progressing positively and PepH3 is a very 
strong candidate to translocate the BBB, the cellular uptake mechanism of this CPP continues to 
be an essential piece of the puzzle in the development and optimization of appropriate strategies 
for therapeutic applications.36 
 
I.4. Cellular uptake mechanisms of cell-penetrating peptides 
The BBB interposes between the systemic circulation and the brain parenchyma determining 
which molecules can cross it into the brain and which ones stay out. However, the brain needs 
essential compounds such as water-soluble molecules, glucose, essential amino acids and 
regulatory factors. Thus the endothelial cells enable the transport of these molecules by two 
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principal systems, an energy-independent direct translocation or an energy-dependent 
endocytosis system.19,21,37 
The energy-independent direct translocation is a passive system where the molecules can 
translocate the BBB by gradient-driven route. There are two pathways, the paracellular route 
(Figure I.3A) translocates the small water-soluble molecules by simple diffusion through the 
small pores in the TJ while small lipid soluble substances dissolve in the lipid plasma membrane 
and are translocated across the transcellular route (Figure I.3B).38,39 
All other molecules such as glucose, essential amino acids and regulatory factors are 
translocated across the BBB via an energy-dependent endocytosis system. This system can be 
sub-divided into five principal pathways: carrier-mediated transport; proton pump efflux 
transporters (efflux pumps); receptor-mediated transcytosis (RMT); adsorptive-mediated 
transcytosis (AMT); and cell-mediated transcytosis.8,16,40 
Carrier-mediated transport is the pathway employed to translocate glucose and amino acids 
through the BBB. In this case, the molecules bind to a transporter on one side of the membrane, 
that through a conformational change, transports them to the other side of the membrane (Figure 
I.3C).16 
The efflux pumps pathway is composed by several transporters such as ATP binding cassette 
(ABC) transporter, P-glycoprotein1 (P-gp) and multidrug resistant protein (MRP). These cell 
membrane proteins are responsible for the ejection of many foreign molecules out of cell 
(Figure I.3D).8,16  
The last three systems are based on the transcytosis concept and this is the main system that 
macromolecules use to translocate across the BBB. Transcytosis designates the movement of 
cargo-packed endocytosed vesicles across the cell membrane, to a target membrane. In the 
membrane, the cargo is sorted in the early endosomal network where it is either recycled to the 
surface membrane or targeted to late endosomes and/or multivesicular bodies. Lastly, we have a 
fusion of cargo-packed vesicles with the target membrane and the consequent release of cargo 
on the other side of membrane. In RMT the macromolecules bind to specific receptors on the 
membrane surface and form a cluster which can translocate the membrane (Figure I.3E). The 
AMT systems requires cationic proteins that interact with the membrane to induce endocytosis 
and then the transcytosis (Figure I.3F). Finally, the cell-mediated transcytosis is a more recently 
identified translocation system that is mainly used by some pathogens (Figure I.3G).8,13,16,40,41 
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Figure I.3 - Schematic representation of the translocation mechanisms across the BBB. There are two principal 
systems, the energy-independent direct translocation (A and B) and an energy-dependent endocytosis system (C to 
G).16 
Several studies, employing Tat and nona-arginine, R9, have shown that these CPPs use three 
different endocytosis pathways belonging to the AMT systems.42 
Internalization via an AMT mechanism is subdivided into clathrin-mediated endocytosis, 
caveolae-mediated endocytosis (or lipid-raft mediated endocytosis) and clathrin- and caveolin-
independent endocytosis.40,43  
Clathrin-mediated endocytosis involves the formation of clathrin-coated vesicles. The first 
step is the nucleation of the cargo and the binding of mediated adaptor proteins followed by the 
recruitment of clathrin for the clathrin coated pit. Subsequently, the large GTPase dynamin 
mediated twisting promotes scission and release of the vesicles. Finally, the clathrin coat is 
removed and the vesicles can fuse with early endosomes. From this compartment, the 
substances may follow a recycling route or they can suffer maturation into late endosomes that 
are then delivered to the other side of the membrane. Eventually the molecules can also be 
degraded in lysosomes (Figure I.4B).44 
The mechanism by which caveolar vesicles (caveolae) are formed, is similar to the one 
described for clathrin-coated vesicles however, the caveolae are flask-shaped invaginations on 
cell surface. These specialized lipid-raft domains are rich in cholesterol and sphingolipids.  The 
vesicles also recruit dynamin but, in caveolin-mediated endocytosis, the structural coat of 
caveolar vesicles is formed by caveolin proteins. Into the caveolae, the molecules can follow the 
same routes previously described or, possibly, be delivered to the Golgi apparatus or the 
endoplasmic reticulum (Figure I.4C).43  
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Macropinocytosis is the best identified clathrin- and caveolin-independent endocytosis 
mechanism and involves a cellular pathway employed when a large quantities of molecules 
needs to translocate the cell membrane. In this mechanism, the cell membrane forms large 
protrusions that are able to capture a large amount of extracellular material then, these close and 
form large intracellular vesicles that may undergo to various destinies. Currently, the final 
destination of the macropinosomes is not yet understood (Figure I.4A).8,16,41,45–47 
 
 
Figure I.4 - Schematic representation of the adsorptive-mediated transcytosis mechanism. There are three principal 
mechanisms, the macropinocytosis (A), clathrin-mediated endocytosis (B), and caveolae-mediated endocytosis (C).  
The scheme was adapted from41,48  
Although, there are several proposed mechanisms for CPP internalization and translocation of 
the BBB, the true mechanism employed by each CPP might be dependent on a variability of 
both chemical and physical factors. The CPPs characteristics such as their sequence, size, 
charge, structure and stability as well as the characteristics of their cargo such as its structure or 
charge can also contribute for their translocation.45,49 For example, the mechanism that allows 
for the translocation of the Tat peptide depends on its cargo. When Tat is conjugated with a 
protein, it uses a lipid-raft mediated endocytosis but, when it is conjugated with a fluorophore it 
uses a clathrin-dependent endocytosis. The peptide concentration as well as the cell type-
dependent composition of the plasma membrane also can contribute for the CPP 
translocation.22,26,47 
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I.5. Strategies to study the cell-penetrating peptides translocation on BBB 
 
I.5.1. Cell models as tools to study the BBB 
The pharmaceutical drug discovery and development processes are divided into different 
stages that culminate with the submission and launch of the final product. The discovery phase 
is very important because it is the phase where in vitro and in vivo studies are performed. 
In the initial phase, choosing the correct models of the BBB is crucial because cell-based 
BBB assays are powerful and flexible experimental tools that allow us to study the transport 
processes and the dynamic functions of the BBB in normal and pathological states. To study the 
response of the BBB and determine its permeability, the in vitro BBB cell models are usually 
isolated from mouse, rat and human tissues. Outside the cost, time and cell capacity, it is very 
important that the model resembles the in vivo conditions and that other important conditions 
are respected, such as a reproducible permeability of reference compounds, a good screening 
capacity, the display of complex tight junctions, adequate expression of BBB phenotypic 
transporters and transcytosis activity. However, the choice of BBB cell model depends on what 
the objective and/or the stage at which the drug discovery experiment is at.15  
 
I.5.2. Application of cell models as tools to study the trafficking pathways 
One of the most important phases on drug discovery is the pharmacodynamics studies as 
well as the BBB permeability studies, time course and determination of free drug concentrations 
in blood and brain. To accomplish these studies, the brain endothelial cells are grown on filter 
inserts together with culture medium at the bottom of culture plates to simulate the physiologic 
conditions (Figure I.5).15,50 
 
 
Figure I.5 - Schematic representation of the in vitro blood-brain barrier model. The filter inserts are placed into 
culture plates to simulate the different parts of the BBB. The endothelial cells are cultured into apical side where are 
applied the samples to simulates the blood side. The base side represent the brain side where culture medium can be 
added. The scheme is adapted from15 
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These modelling can be used for study the trafficking pathways by perturbation of cellular 
transport. Most transport processes are affected by therapeutic agents that can interfere with 
some specific characteristics of cell function or structure. Thus by inhibiting a specific pathway, 
it is possible to understand that the main structures, proteins and other cellular components 
which are essential and involved in CPPs translocation.15,51 
 
I.5.3. Fluorescent labelling to study the trafficking pathways 
As aforementioned, CPPs have a great potential as carriers of various types of cargos into 
cells such as peptides, proteins, including antibodies, nucleotides, siRNA, plasmids, imaging 
agents, drugs and other molecules.22,52 
One the most effective strategies that allow for the study of these delivery proteins is the 
fusion of CPPs with fluorescent probes in order to analyse their location, translocation dynamics 
and to quantify them in both in vitro and in in vivo experiments, through fluorescence 
techniques.  
The principal fluorescent probe employed in this studies is the green fluorescent protein 
(GFP). This protein was isolated from the pacific jellyfish Aequorea victoria and it 
revolutionised cell biological research allowing the visualization of protein dynamics inside 
living cells. The native GFP structure is composed by 238 amino acids making up the 27 kDa 
that form a 11 b-sheets that are arranged in a rigid cylindrical b-barrel structure. The significant 
and stable fluorescence is derived from a triplet of adjacent amino acids, seryne-tyrosine-
glycine at positions 65-67 which are located in the center of a stable barrel structure (Figure I.6). 
The fluorescent specie is formed through a reaction that occurs between the amino acids triplet 
and it exists in two states, a protonated form that absorbs at 395 nm and is the prevalent state of 
GFP and an unprotonated one that absorbs at 475 nm. GFP has a maximum fluorescence 
emission peak at approximately 509 nm (Figure I.7).53–55 
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Figure I.6 - Structure of Green fluorescent protein (GFP). Left: Three-dimensional view of GFP b-barrel structure. 
Right: GFP chromophore is an amino acids triplet (Ser65-Tyr66-Gly67) which are located in the center of GFP b-
barrel structure. The structures shown are based on PDB file 1ema and were produced with Chimera v1.10.1. 
 
 
 
Figure I.7 - Absorption and emission spectrum of  wild type green fluorescent protein (wtGFP). The spectrum shown 
is adapted from Zeiss.56 
Today it is possible to find a broad variety of fluorescent protein genetic variants that have 
been developed to provide a wide range of fluorescence emission spectral profiles that span 
almost the entire visible light spectrum.53–55 
These approaches have expanded and adapted the use of fluorescence labelling allowing it to 
be used in almost every biological study. In live cells, fluorescent proteins are usually employed 
to ascertain the localization and trafficking of proteins, organelles, and other cellular 
compartments.54,57 
 
I.5.4. Fluorescence techniques to study the trafficking pathways 
Fluorescence microscopy of living or fixed cells is an essential technique in biological and 
biomedical sciences to observe the dynamic processes inside the cells and tissues but for each 
 14 
study it is of the utmost importance to choose the best suited system to use. Confocal 
Microscopy and Wide-field are the two principal modes of light microscopy.51,58,59 
In wide-field microscopy the sample is subjected to intense illumination from a mercury or 
xenon arc-discharge lamp. The fluorescence emission is detected by diode array and the 
resulting image can be viewed directly in the ocular or captured by a CCD image sensor and 
viewed in a computer (Figure I.8A).54,60–62 
Confocal microscopy consists of multiple laser excitation sources, a scan head with optical 
and electronic components, electronic detectors (photomultipliers) and a computer for 
acquisition, processing, analysis, and display of the images. The sample is excited by lasers and 
the scan head rasterizes the excitation scans and collects the photon signals that are required to 
assemble the final image. One of the most important components of the scan head is the pinhole 
aperture. Whereas in wide-field microscopy all of the light emitted by sample is captured, 
including light from outside of the focal plane, resulting in a significant amount of the signal 
being due to emitted background light and autofluorescense, the confocal microscope uses a 
pinhole that focuses a spot of light that is centered in the focal plane to eliminate out-of-focus 
light resulting in images of a greater clarity. In this technique the fluorescence emission signal 
that is passed through the pinhole aperture is converted into an analogue electrical signal by the 
photomultiplier that is then converted to pixels (Figure I.8B).54,60–62  
Confocal microscopy presented numerous advantages when compared with conventional 
wide-field microscopy namely, the ability to control the field depth, the reduction of complete 
elimination of background information away from the focal plane and the capability to collect 
serial optical sections (z-stack) from thick samples.54,60–62 
Presently, trafficking itineraries and cellular dynamics are increasingly being analysed 
through a 4D technique, meaning that the analysis is being made in the three spatial dimensions 
over time. Nonetheless, fluorescence recovery after photobleaching (FRAP) and fluorescence 
loss in photobleaching (FLIP) are other modes of microscopy that facilitate the study of 
diffusion of molecules whiting living cells.51,63 
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Figure I.8 - Schematic representation of the two principal modes of light microscopy. A – Principal components of 
wide-field fluorescent microscope; B – Principal components of Confocal microscope. 
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I.6. Subject and objective of this work 
The need to deliver drugs into the brain to treat neurological diseases such as Alzheimer’s 
disease has been a major challenge in recent years. However, as the brain cells need to be 
strongly protected against infections, toxins or other foreigner molecules that may enter the 
bloodstream, the BBB acts as a highly selective permeability barrier that only allows certain 
molecules, needed for metabolism and maintenance of these cells, to cross it, effectively 
separating the circulating blood from the brain tissue. 
Owning the barrier properties, the challenge is not to simply create new drugs to counteract 
on neurological diseases, but trying finding means of bringing these drugs across the BBB into 
the brain where they are needed and where they can fulfil their function. The drug delivery 
system cannot result in lesions to the brain cells or in a change to their permeability. It is 
therefore necessary to develop a system that on one hand leaves the cells intact but on the other 
is efficient in its role of translocating the drug to the brain.   
The discovery and study of cell-penetrating peptides have proven to be a good strategy to 
develop new drug delivery systems to the brain as these peptides can easily cross cell 
membranes, carrying other molecules with the added advantage of being almost free of toxic 
effects. 
Recent studies have shown that the capsid proteins of the Dengue virus may give rise to 
multiple sequences that can be derived into CPPs. Nevertheless, before using an CPP as a drug 
delivery system it is important to understand how it operates, what is its internalization 
mechanisms and if there are any toxicological effects to the cells. 
 
The main purpose of this work is to elucidate the translocation mechanism of PepH3 derived 
from the capsid protein of the Dengue virus. To accomplish this, the PepH3 will be conjugated 
with GFP using molecular biology techniques. Subsequently, the conjugate GFP-PepH3 will be 
cloned into expression vectors and transformed into competent cells. After expression, the 
conjugate will be purified in order to obtain a large amount of protein to perform cellular assays.  
On the second part of this work, the GFP-PepH3 will interact with brain endothelial cells in 
different conditions. Thus, allowing to establish a mechanism of translocation, either through an 
energy-independent direct translocation or an energy-dependent endocytosis system. For a more 
detailed study of an energy-dependent endocytosis pathway, inhibitors of specific cellular 
trafficking pathways will be used. Lastly, these results will be confirmed using fluorescence 
microscopy techniques. Through live-cell images it will be possible to observe the effect the 
peptide and the inhibitors have on the cells as well as the interaction of the GFP-PepH3 in the 
different cellular compartments in order to understand the translocation mechanism of this 
peptide.
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II.  MATERIALS AND METHODS  
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II.   MATERIALS AND METHODS 
All reagents used throughout this work as well as their purity and brand are summarized in 
Appendix Table VI.11. All solutions were prepared with ultrapure deionized (dH2O) water 
filtered through a PES 0.2 µm filter and autoclaved. 
 
II.1. Recombinant Protein GFP-Pep 
The oligonucleotides used in this work were designed using the Thermo Fisher Scientific 
tools and purchased at the same company. Forward sequence that aligns with the initial 
sequence of the gene contains the restriction site for restriction enzyme (NheI or NcoI) 
sequences whereas the reverse sequence aligns with the final sequence of the gene contains the 
restriction site for XhoI, linker and peptide sequences. The primers aliquots were prepared in 
dH2O DNase/RNase free and stored at a concentration of 20 pmol/µL. 
 
II.1.1. Amplification for Polymerase Chain Reaction (PCR) 
The PCR mix solution used for the PCR reaction was prepared according to Table II.1for a 
total volume of 20 µL. For the positive control the following solutions were added: 0.5 µL of 
DEN2C (DNA), 0.3 µL of DEN-sfi F (Primer Forward) and 0.3 µL of DEN-sfi R (Primer 
Reverse) and for the negative control 0.5 µL of dH2O DNase/RNase free were added. 
Table II.1 - PCR mix solution, components and volumes. 
Components Volume (µL) 
DNA 0.5 
Primer Forward 0.3 
Primer Reverse 0.3 
Master Mix (KOD) 10 
dH2O 8.9 
Total Volume 20 
 
PCR amplifications were performed with PCR Thermo cycler (Biometra Tpersonal48, 
Analytikjena) under the following conditions: 
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Table II.2 - DNA PCR amplification conditions. 
Step Conditions 
(1) Polymerase activation 95°C for 2 min 
(2) Denaturation 95°C for 30 sec 
(3)Annealing 60°C for 30 sec 
(4) Extension 70°C for 30 sec 
Repeat steps 2 to 4 30 cycles 
 
Colony PCR amplifications were prepared from four colonies transformed into Escherichia 
coli (E. coli) dH5a competent cells (Thermo Fisher Scientific). Each colony was suspended in 
20 µL of dH2O. 
Table II.3 - Components and volumes for colony PCR mix solution. 
Components Volume (µL) 
DNA 4.7 
Primer Forward 0.15 
Primer Reverse 0.15 
Master Mix 5 
Total Volume 10 
 
Table II.4 - Colony PCR amplification conditions. 
Step Conditions 
(1) Polymerase activation 95°C for 7 min 
(2) Denaturation 95°C for 30 sec 
(3)Annealing 60°C for 30 sec 
(4) Extension 70°C for 30 sec 
Repeat steps 2 to 4 30 cycles 
 
All amplification products were visualized under ultraviolet (UV) light (ChemiDocäXRS+, 
Bio-Rad) in a 2% (w/v) electrophoresis ultrapure grade agarose gel in TBE1x buffer. 
Plasmid DNA was purified with a QIAquick Gel Extraction kit (QIAGEN). Followed by 
DNA precipitation using a sodium acetate solution (20 µL sodium acetate, 500 µL ethanol 
100% and 1 µL glycogen), samples were stored at -80°C. The precipitated DNA was ressuspent 
in dH2O and all samples were quantified using NanoDrop 2000 Spectrophotometer (Thermo 
Fisher Scientific). 
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II.1.2. DNA Digestion 
Amplified sequences were inserted in a pET28a (+) or pETM-10 vector containing a His-Tag 
in the N-terminal.  
For pET28a (+) cloning, sequences were ligated into the NheI and XhoI restriction enzyme 
cleavage sites upstream of pET28a (+) vector. First, DNA was digested with NheI restriction 
enzyme. For the digestion of 1 µg of DNA, it was added 2 µL Tango buffer (10x), 0.5 µL NheI 
(10U, one unit required to digest 1 µg of lambda DNA) and dH2O to make up to a total volume 
of 20 µL, followed by incubation overnight at 37°C. Next, the DNA was precipitated with 
sodium acetate, as previously described. This step is required to exchange buffer components of 
the digestion reaction. For the digestion with XhoI 1 µg of DNA, was added to 2 µL R buffer 
(10x), 0.5 µL XhoI (10U, one unit required to digest 1 µg of lambda DNA) and dH2O to make 
up to a total volume of 20 µL and incubated overnight at 37°C. 
Amplified sequences to be inserted in the pETM-10 vector were digested with the restricton 
enzymes NcoI and XhoI. In this case, the digestion of DNA occurs simultaneously. The 
digestion was performed using 1 µg of DNA, 4 µL Tango buffer (10x), 0.5 µL NcoI (10U), 0.5 
µL XhoI (10U) and dH2O to make up to a total volume of 20 µL and the solution was 
incubating overnight at 37°C. 
Subsequent to the digestion procedure the DNA was purified using a PCR Clean kit 
(QIAGEN) and quantified using NanoDrop 2000 Spectrophotometer (Thermo Fisher 
Scientific). 
 
II.1.3. Cloning and Transformation into competent cells 
For cloning the amplified and digest DNA fragments (200 ng) were inserted into pET28a (+) 
vector in a proportion of 1:3 (200 ng of insert to 65 ng of vector), using a CloneDirect ligation 
kit. For ligation reaction to the respective volumes of insert DNA and vector it was added 2 µL 
of 10x Ligation buffer, 1 µL of CloneSmart DNA Ligase, and dH2O to make up to a total 
volume of 20 µL. The reaction was incubated at 23ºC for 2 hours, and then stopped by 
incubating the reaction at 70ºC for 15 minutes.  
Ten microliters of the plasmid solution were added to 70 µL of  E. coli dH5a competent 
cells (Thermo Fisher Scientific) and incubated in SOB medium at 37ºC, 225 rpm (Incubator 
Orbital Shaker, VWR) for 1 hour. The transformed cells were grown overnight in LB plates 
with 50 µg/mL of Kanamycin. Four random colonies were picked for PCR amplification (see 
the procedure in II.1.1). After amplification two of the colonies were selected for sequencing at 
GATC Biotech. 
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The positive sequences were transformed in E. coli BL21(DE3) competent cells (Thermo 
Fisher Scientific) in the same conditions as those for  E. coli dH5a competent cells. 
For detailed composition and preparation of the medias, please refer to Appendix Table VI.1. 
 
II.2. Protein Expression and Purification  
Cells were grown in 500 mL SB medium (Appendix Table VI.1), supplemented with 
kanamycin (50 µg/mL), at 37ºC  until an OD600 @ 0.6 was reached and then induced with 0.6 
mM IPTG at 25ºC, 200 rpm (Incubator Orbital Shaker, VWR) for  approximately 20 hours. 
Cells were harvested by centrifugation (JE-21M/E Centrifuge, Beckman) at 4°C, 4000 rpm for 
15 minutes. The pellet was re-suspended in 25 mL of Binding buffer with anti-proteases and 
stored at -20ºC. The frozen pellets were thawed at 4ºC and 5 µL of Benzonase (10 µL for 50 mL 
of protein extract) were added. Subsequently the cells were incubated on ice for 30 minutes and 
lysed by sonication on ice for 6 minutes (three 2 minute cycles of 50% pulsing). The lysate was 
cleared by centrifugation (Centrifuge 5418 R, Eppendorf) at 4°C, 13 000 rpm for 45 minutes.  
The supernatants were purified by Metal-Chelate Affinity Chromatography (MCAC) to 
remove the contaminants. The protein extract was purified using a 5 mL HisTrap column (GE 
Healthcare Life Sciences) on an ÄKTA Explorer (GE Healthcare Life Sciences) with a flow of 
1 mL/min. After injection, the protein extract was washed with Buffer A (50 mM Sodium 
phosphate, 1 M NaCl and 10% glycerol, pH 6.8), the proteins that not adsorbed were washed 
out. The protein of interest was eluted employing a discontinuous linear gradient with Buffer B 
(50 mM Sodium phosphate, 1 M NaCl, 500 mM Imidazole and 10% glycerol, pH 6.8) as 
follows: 5% for injection, 12% for washed and 12% - 100% for elution (4 volumes/column) for 
20 minutes. The absorbance of the eluate was monitored at 395 nm, the first GFP absorbance 
pick. To ensure protein stability and further purify the protein extract a molecular exclusion 
chromatography was performed using HiLoad 16/60 Superdex S200 column (GE Healthcare 
Life Sciences) on an ÄKTA Explorer (GE Healthcare Life Sciences) with a flow of 1 mL/min. 
The proteins were eluted with PBS with 1mM DTT and the eluate absorbance was monitored at 
280 nm and 395 nm. A flowchart of these procedures is depicted in Appendix Figure VI.3. 
Protein samples were concentrated with an Amicon® Ultra-15 (Merck) at 4°C, 4000 rpm for 
30 minutes. The concentrated proteins were quantified in a Nanodrop ND-1000 
Spectophotometer (Thermo Fisher Scientific) by measuring the absorbance at 280 nm and 
employing the corresponding extinction coefficient and molecular weight (ProtParam 
Database). Protein quantifications were also confirmed by Bradford Method (Appendix VI.6) 
and protein purity was analysed by SDS-PAGE electrophoresis in 12% of acrylamide gels 
(Appendix VI.7). Protein samples were stored in aliquots at -80ºC in PBS with 1mM DTT and 
10% of glycerol. 
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II.3. GFP-pep Interaction with Brain Endothelial Cells (BECs) 
 
II.3.1. Cell Line and Cell Culture 
Immortalized mouse brain endothelial cell line bEnd.3, purchased from the ATCC®, were 
used to simulated the blood-brain barrier. Cells were cultured in complete Dulbecco’s Modified 
Eagle’s medium (DMEM, Gibco, Thermo Fisher Scientific), supplemented with 10% fetal 
bovine serum (FBS, Gibco, Thermo Fisher Scientific) and 1% Penicillin Streptomycin (Pen 
Strep, Gibco, Thermo Fisher Scientific).  Cells were grown on T-75 flasks in an incubator at 
37°C with 5% CO2 atmosphere and the medium was changed every two days. 
When the adherent monolayer reached 80% confluency, cells were harvest with trypsine 
(Gibco, Thermo Fisher Scientific) and seeded either 3500 cell/well into tissue culture inserts 
(pore size 1 µm, Falcon) coated with fibronectin (Merck) in 24-well plates (Falcon); or 6000 
cell/well in 24-well plates (Costar) without tissue culture inserts. The cells were grown for 9 
days until tight junctions were formed and the media was changed every two days. 
 
II.3.2. Peptide Translocation, Integrity and Internalization in BBB model 
The bEnd.3 cells grown in tissue culture inserts were incubated with 0.5 µM of different 
peptide-conjugates (GFP, GFP-Tat, GFP-PTT and GFP-H3) in DMEM without phenol red with 
10 % FBS during 5 hours at 37ºC, 5% CO2. After incubation, the samples were collected from 
the apical side or apex and base of the inserts. Both apex and base were washed twice with PBS 
and once with complete DMEM without phenol red. Next, 25 mg/mL of Fluorescein 
isothiocyanate-dextran (40 000 wt, FD40, Sigma) was diluted to an absorbance of 0.1 or lower 
and added to the apex. The plates were incubated for 2 hours at 37ºC, 5% CO2 to verify barrier 
integrity. 
The cellular interaction and internalization assays were performed in 24-well plates without 
tissue culture inserts. The cells were incubated with 0.5 µM of different peptides (GFP, GFP-
Tat, GFP-PTT and GFP-H3) in complete DMEM without phenol red during 5 hours at 37ºC, 
5% CO2. After incubation, the samples were collected. To recover the protein membrane 
interaction samples, the cells were washed with cold PBS followed by an acid buffer (100 mM 
NaCl and 50 mM Glycine, pH 2.8) and again with PBS. Volumes from different washes were 
combined to the same eppendorf. Next the cells were lised using RIPA buffer (50 mM Tris-HCl, 
150 mM NaCl, 1% Triton X-100, pH 7.2). Lised cells were collected and soluble proteins were 
cleared by centrifugation (Centrifuge 5418 R, Eppendorf) at 4ºC, 13 000 rpm for 15 minutes. 
All fractions were analysed by fluorescence spectroscopy in a 96-well black plate 
(Eppendorf) with a Plate Reader (InfiniteÒ M200, Tecan). The fluorescence signal of samples 
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with GFP was obtained exciting the samples at 395 nm and recording their emission at 509 nm. 
As for samples with FD40 the fluorescence signal was obtained exciting the samples at 493 nm 
and recording their emission at 560 nm. 
 
 
Figure II.1 - Schematic representation of BBB in vitro studies. First, the peptide translocation studies. In centre, the 
integrity tests. Lastly, the internalization and interaction studies. These studies were performed in bEnd.3 cells. 
 
II.3.3. Metabolic and Endocytosis Inhibition Studies in BBB model 
The metabolic inhibition studies were first performed at low temperature. In order to 
decrease the temperature gradually, the cells were maintained for 30 minutes at room 
temperature before adding the peptide. Cells were incubated with 0.5 µM of different peptides 
(GFP, GFP-Tat, GFP-PTT and GFP-H3) in complete DMEM without phenol red during 5 hours 
at 4ºC. 
The inhibition of Clathrin-dependent and -independent endocytosis was induced by treating 
cells with chlorpromazine (CPZ) and dynasore, respectively, at 50 µM, 30 minutes prior to the 
addition of peptide. The cells were incubated with 100 µM of 5-(N-Ethyl-N-isopropyl)amiloride 
(EIPA) for 30 minutes to inhibited the macropinocytosis mechanism. Methyl-b-cyclodextrin 
(MbDC) was added at 5 mM for 30 minutes prior to the addition of peptide to block the lipid 
raft/caveolae-mediated endocytosis. Brefeldin A was added at 10 µg/mL for 30 minutes to 
interfered with the Golgi trafficking.    
After peptide incubation, samples were collected from the apex and base. Next, the integrity 
of the BBB was evaluated for all inhibitory conditions and controls using FD40 probe, as 
previously described.  
The fluorescence signal of all fractions was measured in a 96-well black plate with a Plate 
Reader (Infinite M200, Tecan) using the same parameters for GFP and FD40 samples. 
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II.4. Cellular pathway of peptide transmigration – Microscopy Studies 
 
II.4.1. Confocal Microscopy – Live-Cell Imaging  
The bEnd.3 cells were seeded 8000 cell/well to 8 well µ-slides (Ibidi). After 7 days, the cells 
were washed twice with PBS and incubated with the peptides in serum-free DMEM without 
phenol red (Gibco, Thermofisher). After peptide incubation, the cells were washed two times 
with cold PBS to remove membrane-bound fluorophores and fluorescent proteins.  
Cell membrane and lysosomes were stained with 5 µg/mL CellMaskÔ Deep Red plasma 
membrane stain (Molecular Probes, Thermofisher) and 100 nM LysoTrackerÒ Red DND-99 
(Molecular Probes, Thermofisher), respectively, for 15 min after peptide addition.  
In order to observe peptide trafficking, cells were incubated with  25 µg/mL transferrin from 
human serum Alexa Fluorâ 568 conjugate for 15 minutes after peptide addition.  
For inhibitory conditions the concentration and periods of incubation were similar to 
described in section II.3.3. 
Cells were visualized in serum-free DMEM without phenol red (Gibco, Thermofisher) in an 
inverted confocal laser point-scanning Zeiss LSM 880 microscope equipped with Diode 405-30, 
DPSS 561-20 and HeNe 633 lasers and a temperature control incubator at 37°C with 5% CO2 
supply. Images were taken with Plan-Apochromat 20x dry objective and 63x oil objective 
(Zeiss). The Z-stacks images were obtained from the centre of the cell with a range of 14.05 
µm. A total of 15 to 20 raw images were collected.  
All images and co-localization analysis were performed with Fiji software (ImageJ v2.0.0). 
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III.  RESULTS AND DISCUSSION 
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III.   RESULTS AND DISCUSSION 
 
III.1. Recombinant Protein GFP-Pep 
In order to study the translocation mechanism of the cell-penetrating peptides (CPPs), two of 
the best studied peptides, Tat and Penetratin, along with our peptide of interest, PepH31, were 
conjugated with green fluorescent protein (GFP). Conjugation was performed by recombinant 
protein technologies, using PCR and followed by cloning in two similar expression vectors, 
pET28a (+) and pETM-10, to test which one would allow for a better protein expression. 
pET28a (+) is a common expression vector employed with recombinant proteins expressed 
in bacteria, nevertheless new expression vectors have been developed to improve the yield of 
cloning and protein expression. pETM vectors are derived from pET (Novagene) and they share 
many common characteristics with pET vectors such as the His-Tag in the N-terminal, a 
protease recognition site and the conserved multiple cloning site (MCS). Studies have shown 
that pETM vectors can be employed in expedite protein production64, due to their start with a 
NcoI recognition site allowing for a simultaneous digestion with two restriction enzymes 
without the need to exchange the digestion buffer as with pET28a (+) vector. 
The first step was the amplification of GFP gene by PCR using a reverse primer that contains 
the peptide of interest, either Tat, Penetratin or PepH3. In order to confirm if amplification was 
successful, the samples were applied into an agarose gel and visualized under UV light. The 
resulting agarose gel is shown in Figure III.1. The positive control consisted of amplification of 
GFP gene using unmodified primers (lanes 4 and 7), and for the negative control the DNA was 
replaced by dH2O (lanes 2, 5 and 8) and using the respective modified primers. In lane 3 we can 
see amplified Nhe-GFP-H3-Xho DNA while in lane 6 and 9 we can observe the amplified Nco-
GFP-H3-Xho and Nco-GFP-Xho DNA, respectively. 
                                                            1	  The PepH3 was designed with two different linkers. One linker is the same as the control (GFP-H3) while the other linker is equal 
to the Tat and Penetratin linker (GFP-sH3).	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Figure III.1 - Inserts after PCR amplification in 2 % TBE agarose gel at 80 V. Lane: 1 – GeneRuler 1 kb DNA 
Ladder (Appendix VI.9); 2 – Nhe-GFP-H3-Xho Negative control (without DNA); 3 – Nhe-GFP-H3-Xho, insert for 
pET28a (+); 4 and 7 – Positive Control (Nhe-GFP-Xho); 5 – Nco-GFP-H3-Xho Negative control (without DNA);  6 
– Nco-GFP-H3-Xho, insert for pETM-10; 8 – Nco-GFP-Xho Negative control (without DNA); 9 – Nco-GFP-Xho. 5 
µL of each sample with 6x loading dye were loaded into each lane. 
 
As seen in Figure III.1, the agarose gel of the PCR products depicts a band with 750 bp, 
similar to the positive control thus showing that amplification was successful. Also we can infer 
that the samples were not contaminated due to the absence of a band in the control lanes (lane 2, 
5 and 6). Next, the bands containing the DNA were purified with a gel extraction kit. The 
purified samples were digested, using the respective restriction enzymes, and purified using a 
PCR clean kit. 
In order to clone the proteins, the amplified and digested DNA fragments were ligated to cut 
pET28a (+) vector (restriction sites: NheI an XHoI) and pETM-10 vector (restriction sites: NcoI 
an XhoI) in a 1:3 proportion. Next, the plasmids were transformed in E. coli competent cells: 
dH5a cells for a good DNA propagation and maintenance; and BL21(DE3) cells for protein 
expression. For negative control no colonies were observed, while for clones at least fifty 
colonies were counted. 
To confirm that the transformation in dH5a cells was successful, four random colonies were 
picked and re-suspended in dH2O for PCR amplification. After confirmation of clones by 
electrophoresis in an agarose gel, the samples were sent for sequencing. Subsequently, 
employing the Basic Local Alignment Search Tool (BLAST) the sequencing results were 
compared with expected nucleotide sequence that will produce the protein of interest, GFP, 
GFP-H3, GFP-sH3, GFP-Tat and GFP-PTT. The positive results were transformed into 
BL21(DE3) cells. 
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III.1.1. Expression and detection of target protein 
Cells were grown at 37ºC until an OD600 @ 0.6 was reached and induced with 0.6 mM IPTG. 
Aliquots were taken at different stages of growth: immediately before cell induction (0 hours) 
and 3, 6 and 24 hours after induction. After each time, the samples were prepared to obtain the 
different cellular fractions: total, soluble and insoluble cellular fraction. The total fraction 
comprises the pellet that was obtained after centrifugation of the initial sample. After 
resuspension of the pellet in binding buffer and centrifugation two fractions were obtained: the 
soluble (supernatant) and insoluble (pellet) fractions. All fractions were analysed by SDS-
PAGE electrophoresis to detect target proteins. Figure III.2 shows the resulting SDS-PAGE gel.  
 
 
Figure III.2 - Fractions collected of pET28a-GFP (A and B) and pETM10-GFP (C and D), SDS-PAGE 12%, 180 V. 
A and C: 1 – Protein Ladder, 2 – Total fraction t=0h, 3 – Soluble fraction t=0h, 4 – Insoluble fraction t=0h, 5 – Total 
fraction t=3h, 6 – Soluble fraction t=3h, 7 – Insoluble fraction t=3h; B and D: 1 – Protein Ladder, 2 – Total fraction 
t=6h, 3 – Soluble fraction t=6h, 4 – Insoluble fraction t=6h, 5 – Total fraction t=24h, 6 – Soluble fraction t=24h, 7 – 
Insoluble fraction t=24h. The green and red arrows indicate where, in the soluble fraction, the interest proteins are 
expected based on their apparent molecular weight. 
The SDS-PAGE gels on Figure III.2 show the different fractions collected at different stages 
of GFP expression in the two different expression vectors employed, pET28a (+) (Figure III.2 A 
and B) and pETM-10 (Figure III.2 C and D). The total fraction is composed by the total cellular 
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extract. After cell lysis there are two fractions: the soluble fraction that encompasses 
cytoplasmic, periplasmic and membrane proteins and the insoluble fraction comprised by 
cellular debris and inclusion bodies. As GFP is a 27 kDa protein its band should appear between 
the 25 and 35 kDa bands from the protein marker. For both expression vectors, at the initial time 
(t=0h), there is no band in this molecular range. This situation was already anticipated since the 
induction of the interest protein with IPTG had just occurred. Over time, for the expression in 
pET28a (+) vector, it is possible to observe a band with a compatible apparent molecular mass 
in all fractions, including the soluble ones. Also, over time, expression in the pETM-10 vector 
yielded a GFP that could only be found in the total and insoluble fractions. As GFP is only 
found in these fractions, seems that this protein is in the inclusion bodies. 
The literature describes that the pETM vectors are designed for rapid subcloning expression 
and subsequent purification. However, our results show the opposite at least for GFP protein. As 
the protein is in the inclusion bodies, the purification process becomes more complex and time 
consuming. Therefore, pET28a (+) is a better vector to express GFP and consequently, their 
conjugates. So, pET28a (+) was the vector chosen to express the proteins. 
 
 
 
III.2. GFP-pep purification 
As a large quantity of pure GFP and GFP-pep was necessary for carrying out the cellular and 
microscopy assays, it was necessary to express both proteins in large scale. To achieve the 
necessary amount of protein the cells were grown in 500 mL SB medium, supplemented with 
kanamycin and induced with IPTG, at 25°C for approximately 20 hours. Then, the cells were 
harvested by centrifugation and lysed by sonication. The lysate was cleared by centrifugation 
and a 25 mL soluble fraction was obtained. Next step was to purify the proteins of interest 
present in the soluble extract. As these proteins have an exposed histidine tag, it allowed them 
to be purified by Metal-Chelate Affinity Chromatography (MCAC) using a 5 mL HisTrap 
column. First, the protein extract was washed with 50 mM sodium phosphate buffer containing 
1 M NaCl and 10% glycerol at pH 6.8 (buffer A) to remove the proteins that did not adsorbed. 
Then a discontinuous linear gradient of 4 column volumes, with 50 mM sodium phosphate, 1 M 
NaCl, 500 mM imidazole and 10% glycerol at pH 6.8 (buffer B) was employed to elute the 
proteins of interest. To monitor protein elution, the absorbance was measured at 395 nm, 
corresponding to the wavelength of the first absorbance pick of GFP. The chromatograms 
depicting the protein elution profiles are displayed in Figure III.3.   
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Figure III.3 - Elution profile of the protein purification in His-Trap 5 mL column. A: GFP, B: GFP-H3, C: GFP-
sH3, D: GFP-Tat, E: GFP-PTT; the blue line represents the absorption at 395 nm and the green line the percentage of 
B buffer that composes the mobile phase. The work flow was 1 mL/min. 
 
After MCAC purification, the collected fraction was injected in a molecular exclusion column to 
further purify it and to ensure protein stability. Protein elution was performed with PBS containing 
1mM DTT using a HiLoad 16/60 Superdex S200 column at a flow of 1 mL/min. The eluate 
absorbance was monitored at 280 nm and 395 nm. The chromatograms of protein elution profile in 
Superdex S200 column are display in Figure III.4. 
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Figure III.4 - Elution profile of the protein purification in a Superdex S200 column. A: GFP, B: GFP-H3, C: GFP-
sH3, D: GFP-Tat, E: GFP-PTT; the blue line represents the absorption at 395 nm and the orange line the absorption 
at 280 nm. 
 
After the molecular exclusion chromatography, the fractions collected were pooled and a 
total volume of 15 mL was retrieved. Protein samples were concentrated and quantified by two 
different methods. In the first method a Nanodrop spectrophotometer was employed and protein 
concentration was determined by measuring the absorbance at 280 nm and employing the 
corresponding extinction coefficient and molecular weight obtained through the ProtParam 
Database by diluting the samples with PBS with 1mM DTT in a 1:2 ratio. The second method 
employed was a traditional Bradford protein assay. Quantification results are showed in Table 
III.1. 
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Table III.1 - Protein quantification by Nanodrop and Bradford methods after purification and concentration. e and 
MW were calculated with ProtParam. 
Sample 𝜺 (M-1 cm-1) MW (Da) Quantification by Nanodrop (mg/mL)  Quantification by Bradford (mg/mL) 
GFP 21890 26954.4 17.18 17.82 
GFP-H3 27390 29735.3 3.94 3.77 
GFP-sH3 27390 29332.9 20.26 14.47 
GFP-Tat 21890 30208.9 2.86 2.85 
GFP-PTT 32890 30966.8 8.58 6.38 
 
 
The protein quantification results are similar in both methods, exception made for the 
quantification of the GFP-sH3 protein where a greater difference between both methods can be 
observed. Whereas the Nanodrop quantification is based solely on the Lambert-Beer equation 
(Absorbance (A) = Extinction coefficient (e) x path length (b) x analyte concentration (c)) that 
correlates absorbance with concentration, the Bradford assay is also more susceptible to the 
amino acid composition of the quantified protein. This method is more susceptible to 
interference by various chemicals that may be present in the protein sample.  
However, we can see that the quantifications are in line with the chromatographic results 
obtained in the purification step, as we can observe a higher peak at 280 nm in the case of 
GFP-sH3, corresponding to a greater amount of protein while GFP-Tat has the lowest peak at 
280 nm, corresponding to a lower protein quantity. 
Figure III.5 shows the electrophoretic profile of the purified protein obtain through 
SDS-PAGE performed with equal concentrations of protein, 15 µg/µL. We can observe a single 
band for each protein, thus we can conclude that the interest proteins were successfully purified. 
We can also observe that the GFP-Tat and GFP-PTT (lane 2 and 3, respectively) have a similar 
molecular weight (30.21 and 30.97 kDa, respectively) while the GFP-sH3 and GFP-H3 (lane 4 
and 6, respectively) have a slightly lower one (29.33 and 29.74 kDa, respectively) and also, by 
observation of lane 5, that GFP that is the lightest of all purified proteins (26.95 kDa). 
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Figure III.5 - SDS-PAGE from the pure protein collected after all chromatographic steps and concentration; 20 µL 
of each sample were loaded into each lane of a 12 % polyacrylamide gel. Lanes: 1 - PageRuler Prestained Protein 
Ladder; 2 - GFP-Tat; 3 - GFP-Ptt; 4 - GFP-sH3; 5 - GFP; 6 - GFP-H3. 
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III.3. GFP-pep interaction with Brain Endothelial Cells 
Cell-penetrating peptides are being considered promising new tools for drug delivery. This 
part of the work, was dedicated to the test of peptides that were previously conjugated with GFP 
in bEnd.3 model cell to understand which of the main mechanisms is used by PepH3 to 
translocate BBB and what are the effects its translocation has on the cells. 
 
III.3.1. Preliminary GFP-pep translocation studies 
Before starting the translocation assays it was necessary to optimize the conditions 
performed. In particular, peptide concentration and their incubation time. Therefore the selected 
concentration range for these assays covered the peptide concentration used in these types of 
experiments, normally in the nM or µM range. As a cellular model system, we selected bEnd.3 
cells because this immortalized mouse brain endothelial cell line can establish barrier 
characteristics, including complex tight junctions, in a more expedite way.  
The bEnd.3 cells grown in the apex of tissue cultured inserts were incubated with four 
different concentrations of GFP-H3, 0.05, 0.1, 1 and 10 µM in Transport buffer (1 M glucose, 1 
M MgCl2, 1 M HEPES, 3% BSA and PBS) at 37°C with 5% CO2. The Transport buffer is 
employed to simulate the physiological conditions. After, 15 min, 5 and 24 hours, the samples 
were collected from the apex and base of the cell culture plates. Cellular uptake was quantified 
by fluorescence spectroscopy. The fluorescence signal of samples was obtained exciting the 
GFP at 395 nm and recording its emission at 509 nm. Figure III.6 shows the quantification 
results for different concentration of GFP-H3 with different time points.  
 
 
Figure III.6 - Concentration and time dependence of GFP-H3. The graph shows the percentage of different GFP-
H3 concentrations in apex and base side at different time points. Error bars represent the standard error of the mean 
(SEM) from triplicates. 
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For different time points, it is possible to observe an increase in the amount of peptide over 
time, mainly after 24 hours where it is possible to observe a higher percentage of GFP-H3 in the 
base. However, after cells observation with an optical microscope (data not shown) it was 
detected that the cellular barrier was destroyed by the 24-hour time point, thereby allowing 
peptide translocation from the apex to the base. At the time point of 15 minutes the percentage 
of GFP-H3 translocation is not significant because most of the peptide is at the apex. This leads 
us to conclude that 15 minutes are not sufficient to allow for a significant amount of peptide to 
translocate the BBB. Also, with a lower peptide concentration and after a five-hour incubation it 
is possible to observe the peptide at both, the apex and the base. It is also showed that for a 
higher peptide concentration, the translocated percentage is approximately 45%. Which is 
similar to the one obtained employing lower peptide concentrations. However, for higher 
peptide concentrations its percentage in the apex is much higher than expected, greater than 
95%, as for the 15 minutes time point. Probably, at higher concentrations, the peptide tends to 
aggregate among themselves leading to an increase in the fluorescence signal. After 24 hours 
this does not happen because the monolayer barrier is destroyed allowing for the passage of 
such peptide aggregates.  
So, for the next assay, cells were incubated for 30 minutes, 5 and 10 hours, at 37°C, 5% CO2 
in transport buffer with 0.1 µM of GFP and their conjugates. 
 
 
 
Figure III.7 - Time dependence of 0.1 µM GFP and their conjugates. The graph shows the percentage of different 
GFP-conjugates in apex and base side at different time points. Error bars represent the SEM from triplicates. 
Figure III.7 shows the recovery percentage of the GFP and GFP-peps at 30 minutes, 5 and 10 
hours. As before, the quantity of peptide that translocated tends to increase over time, as it is 
possible to find a significant percentage of peptide in the apex side after 30 minutes but, after 10 
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hours the largest percentage of peptide is in the base side. However, once more, after 10 hours, 
the cells were once more observed under the optical microscope (data not shown) and it was 
found that the cellular barrier had been destroyed. 
The peptide uptake percentage is influenced by the conditions in which the cells are grown 
and their ability to form a tight junctions’ monolayer. So, in these assays it was extremely 
important to control cellular integrity and to understand the mechanism responsible for their 
instability. Thus, the cells were incubated with 0.1 µM of peptides in transport buffer at 37°C, 
5% CO2. After 5 hours the samples from the apex and base were collected and the cells were 
incubated again with FD40 (fluorescein isothiocyanate-dextran, 40 000 Da) in transport buffer, 
for 2 hours at 37°C, 5% CO2. FD40 is a 40 kDa fluorescently labelled dextran that is commonly 
used to monitor paracellular permeability. This probe had an initial concentration of 25 mg/mL 
and sequential dilutions were done until an absorbance of 0.1 or lower was achieved before 
adding it to the apex. All collected samples were analysed by fluorescence spectroscopy, for 
GFP samples the fluorescence signal was obtain as previously described, while the FD40 signal 
was obtained exciting the samples at 493 nm and recording its emission at 560 nm. 
Figure III.8 shows the results of the translocation assay with peptides incubated for 5 hours 
at 37°C and cellular integrity with FD40 during 2 hours. 
 
 
Figure III.8 - Translocation and integrity assay of different peptide conjugates in transport buffer. A – Translocation 
assay at 37°C; shows the percentage of peptide recovered at apex and base after 5 hours of incubation with 0.1 µM of 
the different conjugates. B – Integrity assay at 37°C; shows the percentage of BBB translocation by FD40 probe. 
Filter is a control without cells and No treatment is a control where the cells were incubated with transport buffer. 
Error bars represent the SEM from triplicates. 
The results in graph A, Figure III.8, show that the percentage of peptide recovered from the 
base side is similar to the one obtained in the assays shown in Figure III.7. The only exception 
is for the recovered percentage of GFP-Tat where that is greater on the base side. To validate the 
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results of the translocation assay it is important to observe the cellular integrity after cell 
incubation with the peptide. Graph B of Figure III.8 shows the percentage of FD40 probe that 
was able to translocate the BBB. These results allow us to understand how integrate was the cell 
monolayer. To achieve two controls were prepared. The filter control results from the 
incubation of FD40 with transport buffer and does not contain cells, while the “no treatment” 
control contains cells that were incubated with transport buffer for 5 hours and then with the 
FD40 probe. The results of the cellular integrity assay show that cells incubated with different 
peptides have a similar translocation percentage to both, the cellular control sample - no 
treatment, and the control without cells, Filter. This being the case, the cellular integrity assay 
suggests that the cellular barrier was destroyed and consequently the results from the 
translocation assay cannot be considered valid since there is no barrier to translocate and 
consequently the peptides can easily traffic between sides.  
In an attempt to explain these results two hypotheses were formulated. The first hypothesis 
was that the cellular barrier was destroyed by either the incubation medium or the transport 
buffer. The second hypothesis was that the cellular barrier was compromised by the peptides as 
the cell penetration properties of CPP delivery agents might be depend on the associated cargo. 
In this case, the CPPs cargo is GFP, a high molecular weight protein that some studies state as 
having the capacity to deliver peptides into mammalian cells. However, in previous results we 
observed that the percentage of GFP translocation is greater than that of GFP-peps. Therefore, 
there is the possibility that the GFP is inducing the peptide translocation and not the other way 
around, as was expected. As the GFP might be the first to interact with the cell membrane, it 
may be perturbing the membrane leading to its destruction;65 The first hypothesis is the most 
likely since the percentage of translocation of the FD40 probe in untreated cells is close to that 
of the control without cells. 
Subsequently, to test the first hypothesis, the GFP and its conjugates were diluted in 
complete DMEM culture medium (with Pen Strep and 10% FBS) to stabilize the cultured cells. 
These were incubated with 0.5 µM of GFP and GFP-peps for 5 hours at 37°C, 5% CO2. After 
sample collecting the cells were incubated with FD40 probe also diluted with complete DMEM 
culture medium. 
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Figure III.9 - Translocation and integrity assay of different peptide conjugates in complete DMEM. 
A - Translocation assay at 37°C; shows the percentage of peptide recovered at the apex and base after 5 hours of 
incubation with 0.5 µM of the different conjugates. B - Integrity assay at 37°C; shows the percentage of BBB 
translocation by the FD40 probe. Filter is a control without cells and “No treatment” is a control where the cells were 
incubated with complete DMEM. Error bars represent the SEM from triplicates of at least two independent 
experiments. 
After performing the translocation assay in complete DMEM instead of transport buffer, we 
can observe a considerable improvement in cell integrity (Figure III.9 B), as the percentage of 
FD40 that translocates the BBB, in the “no treatment” sample, is considerably lower (8.66% ± 
0.18) when compared to the percentage of translocated FD40 on the sample without cells 
(43.24% ± 2.27). Therefore, it can be assumed that the incubation in transport buffer was 
damaging the cellular barrier. 
Figure III.9 A, shows the recovery percentage of the different peptides after a 5-hour 
incubation. Earlier, we hypothesised that the GFP might be maximizing the peptide 
translocation and not the opposite, as expected. However, these results show that the conjugates 
have a higher translocation percentage when compared to the translocation percentage of GFP 
alone, thus we can reason peptides may have a lead role in the cellular translocation of their 
cargo. Nonetheless, reviewing the results of the cellular integrity assay, it is possible to observe 
that the percentage of FD40 that translocates the BBB is higher for the GFP sample than it is for 
the “no treatment” control, which may indicate that the amount of GFP translocated thought the 
cells might be due to the formation of gaps between them. The only samples that display an 
integrity considered good are the GFP-H3 and GFP-PTT conjugates as they exhibit similar 
results to the “no treatment” control, while the other samples display results that are 
characteristic of cells that are not arranged in a cellular monolayer (Figure III.9 B). 
Comparing the results obtained during the translocation assays (Figure III.9 A) for GFP-H3 
and GFP-sH3, we can observe that the BBB translocation percentage between them is similar, 
21.63% ± 4.81 and 21.01% ± 7.51, respectively.  However, when we observe the results of the 
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integrity assay for both samples, we can see that the cells incubated with GFP-H3 present a 
better integrity than ones incubated with GFP-sH3, showing that in this case, the linker has an 
influence on BBB translocation. As described in Chapter I.4, CPPs characteristics such as their 
sequence, size, charge, structure and stability as well as the characteristics of their cargo such as 
its structure or charge can also contribute for their translocation and studies suggested that the 
spacer linker can also contribute to the translocation of the CPP.49 The PepH3 is composed by 
seven amino acids and is linked by twelve amino acids to form the conjugate GFP-H3, while the 
GFP-sH3 linker is composed by six amino acids. When the PepH3 is conjugated with GFP 
employing a short linker its sequence is very short and the conjugate has a BBB translocation 
percentage similar to that of the GFP-H3 peptide, however, as shown by the integrity assays it 
also perturbs the cell monolayer because the percentage of FD40 that translocates the BBB is 
higher for the GFP-sH3 than it is for the “no treatment” control. When the PepH3 is conjugated 
with the bigger linker, it can interact with the cellular membrane and cross the BBB without 
toxic effects as in the B graph of Figure III.9 the FD40 percentage that translocates the BBB is 
lower for the GFP-H3 than it is for the “no treatment” control. The translocation assay (Figure 
III.9, graph A) also demonstrated that the GFP-PTT and GFP-Tat have a higher translocation 
percentage when compared to the translocation percentage of GFP-H3 (23.66% ± 3.63 and 
32,61% ± 9.68, respectively). However, the integrity assay also shows, in Figure III.9, B graph, 
that the GFP-Tat induces a higher perturbation to the cell monolayer then the GFP-PTT, as the 
cells incubated with this peptide displayed a cellular integrity similar to that of the “no 
treatment” control. 
The objective of the CPP, PepH3, is to cross the BBB. However, the CPP may fail to cross it, 
because it might be retained by the cell membrane or because they may remain enclosed inside 
the cells. To assess if any of these cases occurs, cellular interaction and internalization assays 
were performed. For these assays bEnd.3 cells grown in culture plates, were incubated with 
conjugates in the same conditions described for the translocation assays. After 5 hours, the 
medium was collected to simulate the apical side. This collected medium contains the free 
conjugates that were not enclosed inside the cells or did not interact with the cell membrane. 
Then, to recover the protein membrane interaction samples, the cells were washed with cold 
PBS followed by an acid buffer (100 mM NaCl and 50 mM Glycine, pH 2.8) and once again 
with PBS. Next, the cells were lysed using RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
Triton X-100, pH 7.2) and the soluble proteins were cleared by centrifugation to recover the 
peptide that was retained inside the cell. Quantification was performed by fluorescence 
spectroscopy just like in the previous experiments. Figure III.10 shows the results of cellular 
interaction and internalization assays. 
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Figure III.10 - Cellular interaction and internalization of different peptide conjugates in a 0.5 µM concentration in 
complete DMEM at 37°C. Results show the percentage of peptide recovered in a culture plate chamber after 5 hours 
of incubation with 0.5 µM of the different conjugates. Subsequently, the incubation medium was removed and with it 
the free peptide. Then cells were washed to recover the peptides that interacted with the cellular membrane. Finally, 
the cells were recovered and lysed and the peptide that was retained inside them was recovered. Error bars represent 
the SEM from triplicates of at least two independent experiments.  
The results of the cell membrane interaction and internalization are presented in Figure 
III.10. It is possible to observe that the majority of the conjugates, over 90%, are found in the 
culture medium. This is very important, because CPPs aggregation occurs mainly in the cell 
membrane37 thus, this assay was performed to verify if there was a significant amount of peptide 
that interacts with the cellular membrane without cross it. Figure III.10, shows that in what 
concerns the percentage of peptide that interacts with the cellular membrane the GFP-H3 and 
GFP-Tat are the samples that displays a higher percentage of peptide interaction, about 1.81% ± 
1.17 and 1.80% ± 1.11, respectively, while GFP-PTT show 1.45% ± 1.30 interaction with the 
cellular membrane. It is also possible to observe that GFP displays the lowest percentage of 
interaction with the cellular membrane and only, 0.76% ± 0.50 of GFP interacts with the cellular 
membrane. In contrast, GFP without peptide is the protein that shows the higher internalization 
values, 0.8% ± 0.13 but, when GFP is conjugated with peptides the accumulation inside the 
cells was relatively low, less than 0.18%. These results suggest that these peptides can cross the 
BBB with their cargo without being retained in the cellular membrane or inside the cells. Neves 
et al, also showed that PepH3 does not associate to membrane proteins of bEnd.3 cells, 
hypothesising that the translocation mechanism of this peptide might be of an adsorptive-
mediated transcytosis type. However, this hypothesis could only be tested with additional assays 
resorting, for example, to the use of specific inhibitors. 
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III.3.2. Metabolic inhibition studies 
A systematic analysis of intracellular transport pathways can be achieved by analysing the 
effects of inhibiting one or more transport processes. To inhibit energy-dependent transport a 
temperature block can be applied. To perform these assays, bEnd.3 cells were incubated with 
0.5 µM of GFP and GFP-peps in complete DMEM for 5 hours at both 37°C and 4°C. Figure 
III.11 shows the translocation and integrity assays for the different peptide conjugates at 4°C 
while the results obtained after an incubation at 37°C were presented in Figure III.9. 
 
 
Figure III.11 - Translocation and integrity assay for different peptide conjugates in complete DMEM at 4°C. 
A - Translocation assay at 4°C, shows the percentage of peptide recovered at the apex and base after 5 hours of 
incubation with 0.5 µM of the different conjugates. B - Integrity assay performed at 4°C showing the percentage of 
BBB translocation by FD40 probe. Filter is a control without cells and No treatment is a control where the cells were 
incubated with complete DMEM. Error bars represent the SEM from triplicates of at least two independent 
experiments. 
In Figure III.11 A, it is possible to observe that the percentage of recovered peptide from the 
base side is less than 5% for all peptides. Comparing these results with the results obtained at 
37°C (Figure III.9 A) there is a considerable decrease in the peptide quantity that is able to cross 
the cells. In the particular case of our interest peptide, PepH3, the percentage of peptide 
recovered in base side decreases from 21.63% ± 4.81 to 4.63% ± 0.79. These results 
demonstrate that the peptide translocation is inhibited at low temperatures, thus in this stage we 
can propose that the peptide translocation mechanism is energy-dependent. 
The results depicted in Figure III.11 B, shows that at low temperatures the cellular integrity 
is maintained because the results with FD40 for cells incubated with different peptides, are 
similar with the no treatment control. From the comparison of the integrity results at both 
temperatures (Figure III.11 B and Figure III.9 B), it is observable that the integrity at 4ºC is 
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better than at 37°C, thus demonstrating that in this conditions the peptides do not exhibit toxic 
effects. 
Cellular interaction and internalization studies were also performed in an attempt to 
understand if the membrane interactions or peptide internalization is temperature dependent. 
These assay was performed as previously described but changing the temperature for 4°C. 
 
 
Figure III.12 - Cellular interaction and internalization of different peptide conjugates with 0.5 µM in complete 
DMEM at 4°C. The results present the percentage of peptide recovered in a culture plate chamber after a 5-hour 
incubation with 0.5 µM of the different conjugates. Subsequently, the incubation medium was removed and with it 
the free peptide. Then cells were washed to recover the peptides that interacted with the cellular membrane. Finally, 
the cells were recovered and lysed and the peptide that was retained inside them was recovered. Error bars represent 
the SEM from triplicates of at least two independent experiments. 
In Figure III.12 it is possible to observe that over 90% of the peptides are found in the 
incubation medium and less than 0.6% are in the membrane while a nearly null percentage is 
inside the cells. The membrane interaction results are similar to the results obtained at 37°C but, 
the internalization values decreased at low temperature. So, these results suggest that the peptide 
internalization and translocation is inhibited by low temperatures and that the mechanism of 
translocation is energy-dependent. 
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III.3.3. Endocytosis inhibition studies 
As described in Chapter I.4 the CPPs can cross the BBB by two principal systems, an 
energy-independent direct translocation or an energy-dependent endocytosis system. 
Nevertheless, we have shown that an energy-dependent mechanism allows for a better 
explanation of the results obtained. 
Studies with CPPs40,45 have shown that is very common for these peptides to be translocated 
employing several endocytic pathways belonging to the AMT systems. To further explore the 
possibility that PepH3 is able to translocate via an endocytic mechanism, we studied the effect 
of a collection of known endocytic inhibitors had in the peptides ability to translocate the cell 
membrane. Since our previous results show that GFP and GFP-Tat were disturbing the cell 
monolayer, it was decided to carry the endocytosis inhibition studies using GFP-H3 and GFP-
PTT. For these assays, bEnd.3 cells were pre-treated with each inhibitor for 30 minutes prior to 
incubation with 0.5 µM GFP-H3 and GFP-PTT for 5 hours at 37°C, 5% CO2 (Figure III.13 A). 
A cellular membrane integrity test was also performed for each assay and its results are shown 
in Figure III.13 B. 
To inhibit individual endocytic pathways several pharmacological inhibitors were employed: 
EIPA (5-(N-ethyl-N-isopropyl)amiloride) was used to inhibit the macropinocytosis by blocking 
off the Na+/H+ exchange; Chlorpromazine (CPZ) is a cationic amphiphilic drug which prevents 
the formation of clathrin-coated pits by a reversible translocation of clathrin and its adapter 
proteins from the plasma membrane to intracellular vesicles, thereby inhibiting the clathrin-
mediated endocytosis;66,67 Methyl-b-cyclodextrin (MbCD) was used to interfere with the lipid 
raft/caveolin-mediated endocytosis because it has a high affinity for cholesterol and 
consequently, blocks the internalization of several ligands67; and Dynasore that acts as dynamin 
inhibitor. This protein is essential for clathrin-coated vesicle formation in endocytosis, as well 
as for ligand uptake through caveolae, so, by using dynasore it is possible to inhibit both 
mechanisms, the clathrin- and caveolin-mediated endocytosis.68,69 Inside the cell, the vesicles 
that were formed can fused with early endosomes, that can interact with the Golgi apparatus. 
Lastly, Brefeldin A, a protein that disrupts the Golgi trafficking by blocking the formation of 
transport vesicles to and from the Golgi apparatus was employed to understand if these vesicles 
could be retaining the peptides inside the cell.70 
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Figure III.13 - Inhibition and integrity assay of GFP-H3 and GFP-PTT in complete DMEM at 37°C. A – Inhibition 
assays where the cells were pre-treated for 30 minutes with the indicated inhibitor prior to a 5-hour incubation with 
0.5 µM GFP-H3 and GFP-PTT.  B – Integrity assay performed at 37°C showing the percentage of BBB translocation 
by FD40 probe. Filter is a control without cells and No treatment is a control where the cells were incubated with 
complete DMEM. Error bars represent the SEM from triplicates of at least three independent experiments. 
Figure III.13, shows the influence of these inhibitors in peptide translocation. In general, it is 
possible to visualize a decrease in the peptide percentage in the base side and, although the 
percentages between inhibitors are similar, there are some differences between them. As 
previously described dynasore can inhibit two of the main routes leading to peptide 
translocation, clathrin- and caveolin-mediated endocytosis. When the cells were pre-treated with 
50 µM of dynasore the peptide translocation percentage in base side decreases from 21.63% ± 
4.81 to 10.34% ± 3.24 thereby indicating that dynamin might play an important role in the 
translocation mechanism of PepH3. However, analysing the two routes individually, the results 
show that with 50 µM of CPZ inhibitor the peptide translocation percentage decreases from 
21.63% ± 4.81 to 15.19% ± 1.22. This decrease is not significant, suggesting that the peptide 
does not cross the BBB via clathrin-mediated endocytosis. In contrast, when the cells were pre-
treated with 5 mM of MbCD the peptide translocation percentage decreases to 6.75% ± 3.08. 
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Regarding cell integrity (Figure III.13 B) it is possible to ascertain that the cell monolayer may 
have been disrupted, allowing for some of the peptide to translocate. It is also possible to infer 
that the caveolin-mediated endocytosis mechanism might be a favoured as there is a more 
significant decrease in the peptide translocation percentage. It is also possible to observe a 
decrease in the peptide translocation percentage of the cells that were incubated with 100 µM of 
EIPA, from 21.63% ± 4.81 to 5.20% ± 2.40. This observation indicates that the peptide might be 
translocating using the macropinocytosis internalization mechanism as excepted, since this is 
the principal mechanism by which macromolecules internalization occurs. Finally, when the 
cells were incubated with 10 µg/mL of Brefeldin A it was possible to observe that the peptides 
should get from the apex to the base side where it is only possible to recover 7.05% ± 1.43 of 
peptide. This decrease in the peptide translocation percentage may be an indication that the 
peptide’s translocation mechanism is dependent on the formation of vesicles. 
So, to confirm all these hypothesis further specific studies are required to establish a 
mechanism of translocation for these peptides. 
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III.4. Cellular pathway of peptide transmigration – Microscopy Studies 
To confirm that the peptide was internalized, its uptake and intracellular localization were 
monitored by live cell image in confocal microscopy. 
 
III.4.1. Preliminary microscopy studies 
To determine the best conditions to perform the microscopy studies, the peptide was first 
analysed using a wide-field microscope. This is a simple and fast system that allows 
visualization of peptide internalization. 
First, bEnd.3 cells grown in 8 well µ-slides were incubated for 15 minutes, 2 and 5 hours 
with 0.1 µM GFP-H3. After these time points, the cells were visualized with a Zeiss Axiovert 
200M wide-field fluorescence microscope equipped with a green BP filter. 
 
 
Figure III.14 - Live bEnd.3 cells incubated with 0.1 µM GFP-H3 for 15 minutes, 2 and 5 h at 37ºC. Images were 
obtained with a Zeiss Axiovert 200M wide-field fluorescence microscope equipped with a Green BP filter 
(Excitation: 450 – 490 nm and Emission: 515 – 565 nm). The scale bars represent 50 µm. 
In fluorescence microscopy we recovered the signal emitted by fluorescence probes such as, 
in this case, the GFP. In none of the times points that were tested (Figure III.14) was possible to 
record a signal due to a significant background signal.  
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This situation might be due to a large concentration of the peptide in the media causing a 
“green carpet” effect. In an attempt to solve this problem wells were washed with PBS and fresh 
media was added. Nonetheless the problem remained and only for 15 minutes and 2 hours’ time 
points  was possible to visualize some peptide cellular internalization (Figure III.14). Another 
possible explanation can be linked to auto-fluorescence from the media. DMEM contains 
phenol red and riboflavin, and when excited they fluoresce in the same spectral range as GFP. 
Changing these parameters during the optimization process, it was found that the wide-field 
system is unsuitable for our experiments since the auto-fluorescence problem remained (data not 
shown). As described in Chapter I.5.4 the wide-field microscope capture all of the light emitted 
by sample, including light from outside of the focal plane, resulting in a significant amount of 
the signal being due to emitted background light and consequently auto-florescence. In contrast, 
the confocal microscope uses a pinhole that focuses a spot of light that is centred in the focal 
plane to eliminate out-of-focus light resulting in images of a greater clarity. Thus, the following 
experiments were performed in an inverted confocal laser point-scanning Zeiss LSM 880 
microscope.  
In following experiments, prior to peptide incubation in serum-free DMEM without phenol 
red, the bEnd.3 cells were washed twice with PBS to remove the residues of complete DMEM. 
After peptide incubation, the cells were washed again with cold PBS to remove membrane-
bound fluorescent proteins and the images were obtained in serum-free DMEM without phenol 
red. 
 
Figure III.15 - Assays for the determination of the protein concentration necessary to achieve a good fluorescence 
signal. Live bEnd.3 cells were incubated with 0.5 µM (Left images) and 5 µM (right images) of GFP-H3 for 1h at 
37ºC, 5 % CO2. Images were obtained by Z-stack (7/14) by Zeiss LSM880 microscope with a 488 nm laser and a 20x 
objective. A temperature control incubator was employed at 37°C with a 5 % CO2 supply. GFP signal is recorded in 
green. The scale bar represent 25 µm. 
To determine protein concentration necessary to achieve a good fluorescence signal in 
confocal microscopy assays, the same peptide concentration used in the BBB translocation 
model assays was tested. However, as shown in Figure III.15 no fluorescence signal was 
detected when the cells were incubated with the lower peptide concentration (images on the 
left). Thus, peptide concentration was increased to 5 µM for which was possible to record a 
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good fluorescence signal (Figure III.15, images on the right). In addition, using the confocal 
microscope improved the imaging, reducing the effect of the auto-florescence observed for the 
wide-field microscope.  
With the objective of understanding how the peptide traffics through the cell, bEnd.3 cells 
were incubated for 1, 2 and 4 hours with 5 µM of GFP-H3 and then a microscopy assay was 
performed to check the location of the peptide within the cell over time. 
 
Figure III.16 - Peptide cell trafficking over time. Live bEnd.3 cells were incubated with 5 µM of GFP-H3 for 1, 2 
and 4 h at 37ºC, 5 % CO2. Images were obtained by Z-stack (7/14) with a Zeiss LSM880 microscope employing a 
488 nm laser and a 20x objective. A temperature control incubator was employed at 37°C with a 5 % CO2 supply. 
GFP signal is recorded in green. The scale bar represent 25 µm. The arrow points to the location of the interest cell. 
The results presented in Figure III.16 show that at one-hour incubation the peptide is 
scattered throughout the cell. However, after a 2 and a 4 hours’ incubation the protein is located 
in specific cellular compartments. From these results we can hypothesise that a peptide 
incubation of 1 hour might have concentrated the peptide in the cellular membrane. And that, 
over time its location is more restricted inside the cell. However, to apprehend into which cell 
compartment the peptide is driven it is necessary to label it with a fluorescent probe. 
 
III.4.2. Fluorescent labelling to locate the GFP-H3 in cells 
To understand the cellular compartments in which the peptide traffic and localize, organelle 
specific fluorescence probes were used. Since, the peptide is conjugated with GFP, RFP was 
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selected as the fluorescent probe for organelles in order to distinguish the labelled organelles of 
the labelled peptide. This allows us to obtain a yellow signal if the peptide interacts with a 
particular cellular compartment. 
When the cells are incubated with the peptide, the first cellular structure it will encounter is 
the cellular membrane. Thus, to visualize cell membranes it used 5 µg/mL of CellMaskÔ Deep 
Red plasma membrane stain for 15 minutes after peptide incubation. CellMaskÔ is composed 
of amphipathic molecules that offer a lipophilic moiety for membrane loading and a negatively 
charged hydrophilic dye that allows its “anchoring” to the plasma membrane. 
To study the peptide interaction with membrane, the cells were incubated with 5 µM at GFP-
H3 during 30 minutes, 1, 2 and 3 hours. Figure III.17, shows the results obtained at these time 
points. At 30 minutes the peptide appears to be outside of the cells, in the medium, where some 
peptide aggregates are visible. However, after 1 hour, the images confirm the previously 
obtained, the peptide is found throughout the cell but when both fluorescence signals are 
merged, a co-localization was not observed which probably means the peptide is inside the cell. 
At 2 hours, the images reveal that peptide is inside the cells, apparently in specific 
compartments. Moreover, at 3 hours, we can observe the peptide inside the cell but it is also 
possible to observe peptide and aggregates outside the cell. Apparently, the GFP-H3 crosses the 
cell membrane very quickly because no co-localization signal was observed for tested 
time-points. However, these results suggest that the peptide can cross into the cell and exit at a 
later time. 
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Figure III.17 - Membrane interaction experiment of PepH3. Live bEnd.3 cells were incubated with 5 µM of GFP-H3 
for 30 minutes, 2 and 3 h at 37ºC, 5 % CO2. Images were obtained with a Zeiss LSM880 microscope employing 488 
and 633 nm lasers and a 63x oil objective. A temperature control incubator was employed at 37°C with a 5 % CO2 
supply. GFP signal is recorded in green while the deep red signal is recorded in red. The scale bar represent 25 µm. 
As previous described, after crossing the cellular membrane the peptide might form vesicles 
that fuse with early endosomes that may follow different routes. Transferrin, for example, is a 
monomeric serum glycoprotein that binds up to two Fe3+ atoms. It is processed in the late 
endosomes, after which the transferrin receptors are recycled via a recycling endosome to the 
plasma membrane.71,72 Transferrin conjugates can be used to observe transferrin trafficking in 
living cells and is mainly used in endocytosis investigation assays since it allows the 
observation various endosomes and lysosomes. So, to observe the peptide localization inside the 
cells, these were incubated with 5 µM of GFP-H3 for 1, 2 and 3 hours, as at these time points it 
was possible to observe the peptide inside the cells. Then, the cells were washed with cold PBS 
and incubated for 15 minutes with 25 µg/mL of transferrin from human serum Alexa Fluorâ 568 
conjugate. 
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Figure III.18 - Endosomal localization experiment of PepH3. Live bEnd.3 cells were incubated with 5 µM of GFP-
H3 for 1, 2 and 3 h at 37ºC, 5 % CO2. Images were obtained with a Zeiss LSM880 microscope employing 488 and 
633nm lasers and a 63x oil objective. A temperature control incubator was employed at 37°C with a 5 % CO2 supply. 
GFP signal is recorded in green while the deep red signal is recorded in red. The scale bar represent 25 µm. The 
arrow points to the co-localization signals. 
Figure III.18 shows the peptide trafficking over time. With 1-hour incubation, it is possible 
to observe the peptide inside the cells and when the channels are merged it is possible to 
observe some co-localization. However, after a 2 and a 3-hour incubation the co-localization’s 
fluorescence signal is more intense. Probably, after a 2-hour incubation the peptide may be 
located in the early endosomes but after the 3-hour incubation the peptide might be in recycling 
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or late endosomes or in the lysosomes. The main function of these last organelles is the 
destruction of various biomolecules. This being the case, if the peptide is retained in the 
lysosomes, it will eventually be destroyed. Therefore, to test this hypothesis, the cells were 
labelled with a lysosome probe. 
LysoTrackerÒ Red DND-99  is an acidotropic probes that is linked to a weak base that is 
only partially protonated at neutral pH, and that is freely permeant to cell membranes and 
typically concentrates in spherical acid organelles. In these assays, the cells were incubated with 
5 µM of GFP-H3 for 4 hours. After peptide incubation, the cells were incubated with 100 nM of 
LysoTrackerÒ Red DND-99 for 15 minutes. 
 
 
Figure III.19 - Lysosomes localization experiment of PepH3. Live bEnd.3 cells were incubated with 5 µM of GFP-
H3 for 4 h at 37ºC, 5 % CO2. Images were obtained with a Zeiss LSM880 microscope employing 488 and 561nm 
lasers and a 63x oil objective. A temperature control incubator was employed at 37°C with a 5% CO2 supply. GFP 
signal is recorded in green while the deep red signal is recorded in red. The scale bar represent 25 µm. 
The microscopy images displayed in Figure III.19 shows that a large amount of peptide is 
inside cells. However, co-localization of GFP with lysosomes is reduced or inexistent, revealing 
that the peptide escapes this degradative cellular organelle. 
To complete the work presented it was intended to label other cellular compartments, such as 
plasma membrane, actin, early endosomes, and lysosome. However, for the labelling of these 
compartments is required to use a different approaches, either immunostaining using antibodies, 
which requires cell fixation; or using transfection of specific proteins, using CellLightÒ 
reagents. It was decided to use the last since it enable live imaging and avoids unwanted effects 
of cellular fixation. The CellLightÒ reagent, is a new fluorescent protein-signal peptide fusion 
that provides precise and specific targeting of cellular structures in live-cell imaging. These 
reagents are transfected and expressed in cells to label a specific compartment. According to the 
product protocol, the CellLightÒ reagent works better in concentrations between 10 and 50 
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particles per cell (PPC) and that it should be transfected when the cells show a confluence of no 
more than 70 % during 16 hours or more.  
To test this reagent with bEnd.3 cells it was used CellLightÒ for lysosomes, once it could be 
compared with LysoTrackerÒ. After testing different incubation times and different PPCs, the 
transfection was not efficient in bEnd.3 cells (data not shown). In addition, some toxic effects 
were observed, cell doubling time increased and cell morphology was different from healthy 
cells. Thus, staining of remaining compartments with this reagent was discontinued. 
 
III.4.3. Endocytosis inhibition studies by confocal microscopy 
In order to understand the endocytotic mechanism used by PepH3 to translocate the BBB 
and to confirm the results obtained through the BBB model, the cells were observed with a 
confocal microscope in the presence of endocytic inhibitors. These assays were performed in 
same conditions that the inhibition studies in the BBB model. The results obtained are presented 
in Figure III.20. The microscope parameters were adjusted from the fluorescence signal of the 
control sample (No drug). In this control sample the cells were incubated solely with GFP-H3, 
and no inhibitors were added. 
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Figure III.20 - Screening of PepH3 cellular internalization routes. Live bEnd.3 cells were pre-treated with the 
indicated inhibitor prior to its incubation with 5 µM of GFP-H3 for 4 h at 37ºC, 5 % CO2. Images were obtained with 
a Zeiss LSM880 microscope employing a 488 nm laser and a 63x oil objective. A temperature control incubator was 
employed at 37°C with a 5% CO2 supply. GFP signal is recorded in green. The scale bar represent 25 µm. 
In Figure III.20, the green colour shows the GFP signal emitted by GFP-H3 in different 
conditions. After the cells were incubated solely with GFP-H3, and no inhibitors were added 
(No drug sample) we can observe a good fluorescence signal into the cells.  
In general, the results obtained in these assays are similar to those attained in in vitro studies. 
When the inhibitor dynasore is present, it is not possible to observe the peptide inside the cells 
and those found in the extracellular medium have aggregated. As for the pre-incubation of cells 
with CPZ it had no detectable effects in the peptide translocation. However, in contrast, the 
incubation of the cells with MbCD inhibits peptide translocation.  
When the cells are incubated with EIPA it is possible to observe that the inhibition of peptide 
translocation is related to its concentration. Some inhibitors, such as EIPA, have a concentration 
range where they are effective. In this case, the literature suggests that EIPA is effective in the 
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range of 50 to 100 µM. At a concentration of 50 µM we can see that there are peptides in the 
cells as in the control sample, not incubated with inhibitors. In opposition, at a concentration of 
100 µM, no peptide is observed in the cells.  
After a pre-incubation of the cells with Brefeldin A no observable peptide is found in the 
cells, however it is possible to observe a fluorescence signal in extracellular media. Once the 
peptide is incubated after the incubation with the inhibitor, these extracellular peptides are 
probably, peptides that could not translocate into the cell or are peptides that may have been 
internalized but were removed from the cell by other pathways that do not require interaction 
with the Golgi apparatus. 
The results obtained in in vitro assays, show that PepH3 internalization is sensitive to MbCD 
and EIPA, suggesting that PepH3 might be internalized through a lipid-raft/caveolin-mediated 
endocytosis or macropinocytosis. However, the internalization route is also dependent on the 
peptide cargo. GFP is a large cargo that may drive the peptide to be internalized via a 
macropinocytosis route. Moreover, dynamin was shown to have an important role in peptide 
internalization because no peptide was observed inside the cells but, large amount of peptide 
aggregates was visible in extracellular media and the image obtained in visible light shows that 
the cells do not exhibit their normal morphology. Probably peptides concentrated on the 
membrane but, the formation of endocytic vesicles could not be completed due to the inhibition 
of dynamin. As the concentration of peptides in the outside of the cellular membrane increases 
the aggregates that are visible in the image are formed. In the case of Brefeldin A, the in vitro 
results show that the membrane monolayer was perturbed but, as seen in the visible microscopy 
images, a normal cellular morphology is observed.  
Globally, the results show that an endocytic process may be involved in the route of PepH3 
internalization.  
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IV.   CONCLUSIONS, FINAL REMARKS AND FUTURE WORK 
In recent years, cell-penetrating peptides (CPPs) have been investigated for their ability to 
deliver various cargoes, such as therapeutic biomolecules, across membranes and biological 
barriers, being potential effective vehicles in advanced treatments of CNS (central nervous 
system) diseases. Despite the large number of prospective applications of CPPs, the mechanism 
by which translocation of the blood-brain barrier (BBB) occurs remains essentially unknown. 
Currently, little is reported in the literature concerning the BBB translocation mechanism of 
these peptides and a good CPP may eventually not be a good BBB translocator. For example, in 
the case of PepH2 and PepH3, the latter has good translocation capacity while PepH2 heavily 
associates to cellular membranes and accumulates inside cells. 
The main propose of the present work was to understand the mechanisms whereby PepH3, 
derived from the supercharged protein DEN2C, translocates the BBB.  
Before exploring the translocation mechanisms, we started by conjugating the peptide with 
GFP. The recombinant sequences were amplified by PCR and cloned into two different 
expression vectors, pET28a (+) and pETM-10. We observed that, when expressed in the 
pETM-10 vector, the protein was retained in inclusion bodies (insoluble fraction), making its 
isolation more difficult. However, when the protein was expressed in pET28a (+) high levels of 
expression were obtained in the soluble fraction, simplifying its isolation and purification. 
Therefore, pET28a (+) was used to express all GFP conjugates. 
In the second part of this work, the conjugates were tested in an in vitro BBB model, 
consisting of a bEnd.3 cell monolayer. In order to optimize the assay conditions, different 
peptide concentrations were used. Higher concentrations of peptide caused the formation of 
aggregates and consequent destruction of the cell monolayer. On the other hand, with a lower 
peptide concentration there was little peptide translocation. Therefore, the optimal concentration 
for in vitro assays was established between 0.1 µM and 1 µM. All in vitro assays were 
performed applying 0.5 µM of peptide conjugates. Another limiting factor in in vitro BBB 
assays is the buffer/medium used. It was shown that for long incubations (higher than 2 hours) 
the integrity of bEnd.3 cells monolayer was lost when transport buffer was used. In brief, the 
best conditions were obtained when the cells were incubated with 0.5 µM of GFP-H3 in 
complete medium for 5 hours at 37°C, 5 % CO2, with 21.63% ± 4.81 of peptide was able to 
translocate the BBB.  
To assess the mechanism by which novel peptide (GFP-H3) and other known CPPs (GFP-
Tat and GFP-PTT) translocate the BBB, it was first tested a temperature block (4°C). By 
lowering temperature, the translocation of GFP-H3 decreased to 4.63% ± 0.79, suggesting that 
GFP-H3 cellular uptake occurs through an energy-dependent mechanism. To analyse this effect 
further ATP depleted environment (using sodium azide) could also be tested.73 
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The various cellular trafficking processes can be blocked using specific inhibitors. Our 
results reveal that the GFP-H3 requires dynamin for an efficient uptake but does not need 
clathrin. Additionally, both in vitro and confocal microscopy studies, suggest that GFP-H3 uses 
the lipid-raft/caveolin-mediated endocytosis because the cellular uptake is inhibited by dynasore 
and MbCD. Moreover, the GFP-H3 internalization is also inhibited by 100 µM of EIPA, 
revelling that GFP-H3 can also translocate the BBB by macropinocytosis. Together the use of 
temperature block and inhibitors prove that GFP-H3 uses an endocytic route for BBB 
translocation.  
The labelling of specific cellular compartments such as cellular membrane, endosomes and 
lysosomes aided to clarify which compartments GFP-H3 co-localize. For the time points tested 
was not possible to observe co-localization with the cellular membrane. Either peptide 
internalization was to fast to be recorded or internalization occurs at a single molecule level, 
which confocal microscopy is not sensitive enough to detect. In addition, GFP-H3 is using an 
endocytic route in which endosomes are involved. However, GFP-H3 escapes the degradative 
conditions of the lysosomes, since no co-localization with this compartments was visualized 
(Figure III.19). Therefore, we have demonstrated the GFP-H3 is internalized via a route 
dependent of dynamin and lipid-rafts, in addition macropinocytosis seems to also play a role, 
probably by taking up protein aggregates. Following membrane internalization, GFP-H3 is 
sorted in early endosomes and by escaping the lysosomes appears to follow the recycling route 
being exocytosis. Yet, complementary studies are required to confirm the translocation 
mechanism.  
To further elucidate the internalization mechanisms and intracellular trafficking it is 
important to test other inhibitors as well as new labels for specific cellular compartments. For 
example, we can use poly-L-lysine as membrane charge neutralizer to study the interaction of 
the peptide with the cellular membrane.5 
One hypothesis to confirm the endocytosis pathways is through the study of Rho and Rac. 
These are two GTPases involved in cytoskeletal reorganization and endosomal trafficking. Rac 
is located near the plasma membrane and initiates actin polymerization at the start of 
macropinosome formation, while Rho is downstream of multiple endocytic pathways, including 
caveolin-mediated and clathrin-independent endocytosis.49 To study the intracellular route we 
can label the early endosomes as well as the recycling and late endosomes by immunostaining 
using specific antibodies.  
To confirm the qualitative microscopy results it would be important to perform a quantitative 
analysis to detect the amount of peptide that is within the cells and within a specific cellular 
compartment. Subsequently, these results would be compared to other quantitative techniques 
such as flow cytometry.  
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Subsequently, it is also important to conjugate the PepH3 with a therapeutic drug in order to 
verify if cargo alterations can influence the translocation mechanism and, in addition, peptide 
stability under physiological conditions should be tested in mouse and human serum to ensure 
its efficiency before in vivo experiments.  
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VI.   APPENDIXES 
 
VI.1. Protein Sequences 
GFP 
MGVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVK
FEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIE
DGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGIT
LGMDELYK 
Molecular weight: 26954.4 Da 
Ext. Coefficient: 21890 M-1 cm-1 
 
GFP-TAT 
MGVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVK
FEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIE
DGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGIT
LGMDELYKSGGGGSGRKKRRQRRRPPQ  
Molecular weight: 30208.9 Da 
Ext. Coefficient: 21890 M-1 cm-1 
 
GFP-PTT 
MGVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVK
FEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIE
DGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGIT
LGMDELYKSGGGGSRQIKIWFQNRRMKWKK  
Molecular weight: 30966.8 Da 
Ext. Coefficient: 32890 M-1 cm-1 
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GFP-H3 
MGVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVK
FEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHKVYITADKQKNGIKVNFKTRHNIE
DGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGIT
LGMDELYKSGGGGSGGGGSSAGILKRW 
Molecular weight: 29735.3 Da 
Ext. Coefficient: 27390 M-1 cm-1  
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VI.2. Map of vector pET28a (+) 
 
 
 
Figure VI.1 - Map of expression vector pET28a (+), Novagen. 
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VI.3. Map of vector pETM-10 
 
 
 
 
Figure VI.2 - Map of expression vector pETM-10, EMBL Protein Expression and Purification Facility. 
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VI.4. Growth media 
 
 
Table VI.1 - Composition of all growth media used in this work. 
 SB SOB LB LB agar 
Tryptone 24 g 16 g 8 g - 
Yeast extract 16 g 4 g 4 g - 
NaCl - 0.4 g 8 g - 
MOPS 8 g - - - 
1M KCl - 2 mL - - 
1M MgCl2 - 8 mL - - 
LB agar - - - 28 g 
Final Volume of dH2O 800 mL 800 mL 800 mL 800 mL 
 
 
The pH of the LB agar solution was measured with a GLP 21 pH Meter (Crison), and 
adjusted to pH 7 with NaOH. All solutions were autoclaved. After sterilization, the antibiotic 
Kanamycin was added (50 µg/mL). 
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VI.5. Cell soluble extract preparation and purification flowchart 
 
 
Figure VI.3 - Cell soluble extract preparation and purification flowchart. 
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VI.6. Protein Quantification by Bradford Method 
 
The Bradford method is a simple and precise colorimetric assay to determine the protein 
concentration. This method was used to confirm the protein quantification done by NanoDrop. 
Sample preparation followed the manufacture’s indications (Bio-Rad). 
In order to use the correct concentration of BSA (0.1 mg/mL), the absorbance of the solution 
was measured at 279 nm. The theoretical and corrected concentration of BSA as well as the 
respective absorbance at 595 nm for calibration curve as showed in Table VI.2. 
The protein concentration was determined applying the resulting equation from the 
calibration curve (Figure VI.4). 
 
Table VI.2 - Protein concentration and absorbance values used for BSA calibration curve. MW:66400 Da; e:43824 
M-1 cm-1 
[BSA] (µg/mL) [BSA]corrected (mg/mL) Abs595nm 
8 0.0072 0.223 
12 0.0108 0.328 
20 0.0180 0.515 
40 0.0360 0.903 
 
 
 
 
Figure VI.4 - BSA calibration curve used for protein quantification by Bradford method. Absorbance measured at 
595 nm. Equation: y=23.328x + 0.0727; R2=0.99653. 
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VI.7. Gel Electrophoresis  
Polyacrylamide gel electrophoresis was performed in denaturant conditions SDS-PAGE to 
analyse the purified proteins. The gels were prepared as showed in Table VI.3 with 12% (w/v) 
polyacrylamide. 
 
Table VI.3 - Preparation of a 12% polyacrylamide gel. 
 Stacking gel (4%) Resolving gel (12%) 
30% Acrylamide/bis 1.98 mL 6 mL 
0.5 M Tris-HCl, pH 6.8 3.78 mL - 
1.5 M Tris-HCl, pH 8.8 - 3.75 mL 
10% SDS 150 µL 150 µL 
dH2O 9 mL 5.03 mL 
TEMED 15 µL 7.5 µL 
10% APS 75 µL 75 µL 
Total volume 15 mL 15 mL 
 
All samples were prepared with the addition of 20 µL of loading buffer to 3 µg/mL of 
sample. Samples were incubated at 100°C for 10 min. After incubation, samples were loaded 
into a gel and placed in 1x running buffer. Initially samples were run at 140 V, when in the 
stacking gel portion, and then the voltage was increased to 180 V during resolving gel portion. 
 
Table VI.4 – Composition of loading buffer solution. 
Laemmli buffer  
4% SDS 0.4 g 
10% b-Mercaptoethanol 1 mL 
20% Glycerol 2 mL 
0.004% bromophenol blue 1.6 mL 
125 mM Tris-HCl, pH 6.8 5.4 mL 
Total volume 10 mL 
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Table VI.5 – Tris-Glycine buffer composition. 
Running Buffer 10x Prepared 
Tris 25 mM 
Glycine 190 mM 
SDS 0.1% 
 
 
Running buffer 10x was diluted to 1x with H2O.   
 
Electrophoresis gels were prepared with a Mini-Protean Tetra Cell System (Bio-Rad) using 
8.3 x 7.3 cm handcast gels. The molecular weight marker used for SDS-PAGE was PageRuler 
Prestained Protein Ladder (Fermentas), consisting in a mixture of ten native proteins (10 to 180 
kDa). An electrophoresis profile of the marker is despite in Figure VI.5. 
 
 
Figure VI.5 - Electrophoretic profile of Fermentas PageRuler prestained protein ladder  in a 4-20% Tris-glycine gel 
(SDS-PAGE). 
After running, gels were stained by immersion on a Coomassie Brilliant Blue staining 
solution and the excess dye was removed by immersion on a distaining solution. The 
composition of each of these solutions is presented below. 
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Table VI.6 – Composition of Coomassie blue dye solution. 
Coomassie Brilliant Blue – 
Staining Solution  
Coomassie Brilliant Blue 0.5 g 
50% Methanol (v/v) 250 mL 
10% Glacial Acetic Acid (v/v) 50 mL 
40% H2O 200 mL 
Total volume 500 mL 
 
 
 
Table VI.7 – Composition of Distaining solution. 
Distaining Solution  
40% Methanol (v/v) 200 mL 
10% Glacial Acetic Acid (v/v) 50 mL 
50% H2O 250 mL 
Total volume 500 mL 
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VI.8. Preparation of Solutions 
 
 
Table VI.8 – Composition of PBS solution. 
PBS  
137 mM NaCl 8 g 
2.7 mM KCl 0.2 g 
10 mM Na2HPO4 1.44 g 
1.8 mM KH2PO4 0.24 g 
Final volume with H2O 1 L 
Adjust the solution pH to 7.4 and sterilized by autoclave. 
 
  
Table VI.9 – Composition of RIPA buffer. 
RIPA Buffer  
50 mM Tris-HCl 0.788 g 
150 mM NaCl 0.8766 g 
1% Triton X-100 1 mL 
Final volume with H2O 100 mL 
Adjust the solution pH to 7.2 and sterilized by autoclave. 
 
Table VI.10 – Composition of Acid buffer. 
Acid Buffer  
10 mM NaCl 0.5844 g 
50 mM Glycine 0.375 g 
Final volume with H2O 100 mL 
Adjust the solution pH to 2.8 and sterilized by autoclave. 
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VI.9. Gene Ladder 
 
 
Figure VI.6 - Electrophoretic profile of Fermentas GeneRuler 1 kb DNA ladder  in a 1% (w/v) agarose gel in  1x 
TAE buffer. 
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VI.10. Reagent List 
 
Table VI.11 – Brand and purity of the reagents used in this work. 
Reagent Purity Brand 
30% Acrylamide/bis - Bio-Rad 
Agarose Molecular Biology grade in range of 50bp-50kb - GeneOn 
Agarose Ultrapure grade - Nzytech 
Ammonium Persulfate (APS) - Bio-Rad 
Anti-proteases cocktail-EDTA free - Roche 
BenzonaseÒ Nuclease 25 U/µL >90% Merck 
Brefeldin A ³99% Sigma-Aldrich 
Bromophenol Blue  - Bio-Rad 
BSA ³98% Merck 
Cell Mask Deep Red -    Thermo Fisher Scientific 
Chlorpromazine hydrochloride ³98% Sigma-Aldrich 
Coomassie Brilliant Blue - Bio-Rad 
Dimethyl sulfoxide (DMSO) ³99.8% Merck 
Dithiothreitol (DTT) ³98% Sigma-Aldrich 
DNA Orange Loading Dye - Fermentas 
Dulbecco’s Modified Eagle’s Medium (DMEM) - 
Gibco – Thermo Fisher 
Scientific 
Dulbecco’s Modified Eagle’s Medium (DMEM), no 
phenol red 
- 
Gibco – Thermo Fisher 
Scientific 
Dynasore hydrate - Sigma-Aldrich 
Ethanol 99.85% Merck 
FD40 - Sigma-Aldrich 
Fetal Bovine Serum - 
Gibco – Thermo Fisher 
Scientific 
Fibronectin Bovine Plasma  - Calbiochem 
Glacial Acetic acid 99.80% Merck 
Glucose  ³99.5% Sigma-Aldrich 
Glycerol anhydrous Molecular Biology Grade 99.50% AppliChem 
Glycine  ³99% Sigma-Aldrich 
Glycogen - Roche 
Green safe - Nzytech 
Imidazol ³99% Merck 
Isopropanol ³99.8% Merck 
Isopropyl b-D-1-thiogalactopyranoside (IPTG)  ³99% Sigma-Aldrich 
Kanamicin Sulphate -    Merck 
LB agar - AppliChem 
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LysoTracker Red DND-99 - Thermo Fisher Scientific 
Magnesium Chloride - Merck 
Methanol 99.80% Merck 
Methyl-b-cyclodextrin - Sigma-Aldrich 
MOPS - Merck 
O’Gene Ruler Ladder 1kB - Fermentas 
PCR Master Mix – Supreme NZyTaq 2x green - nzytech 
Penicillin-Streptomycin (Pen Strep) - 
Gibco – Thermo Fisher 
Scientific 
Poly-L-Lysine - Sigma-Aldrich 
Potassium chloride - Merck 
Potassium dihydrogen phosphate 99.5% Merck 
Protein Ladder - Thermo Fisher Scientific 
Running buffer: Tris/Glycine/SDS - Bio-Rad 
Sodium Acetate ³99% Sigma-Aldrich 
Sodium chloride - Merck 
Sodium dihydrogen phosphate monohydrate 99% Merck 
Sodium dodecyl sulphate (SDS) ³99% Merck 
Sodium phosphate 96% Sigma.Aldrich 
TAE 50x - Nzytech 
TBE 10x - Nzytech 
TEMED ³99% Merck 
Tris-HCl - Merck 
Triton X-100 - Merck 
Trypsin - 
Gibco – Thermo Fisher 
Scientific 
Tryptone USP - Biokar Diagnostics 
Yeast Extract - Biokar Diagnostics 
b-Mercaptoethanol ³99% Merck 
 
 
 
